Page [ADDRESS_1121893] 02019927  
Approved by [CONTACT_811064] 15, 2015 
Page 2 of 84 
SPONSOR OVERVIEW  
Evaluation of the Effectiveness of Transcorneal Electrical Stimulation to Improv e Visual 
Function Following Ocular Trauma 
Departme
nt of Defense 
Grant# W81XWH-12-2-0097 
Study Design: 
Sponsor: 
Scientific Program Officer:  
Principal Investigator : [INVESTIGATOR_811045], randomized, SHAM controlled, c linical trial 
Department of Defense 
US A rmy Medical R esearch A cquisition  Activity 
Defense Medical R esearch and Development  Program 
[ADDRESS_1121894] in Chief 
 
      

Page 3 of 84     
PROTOCOL SYNOPSIS  
Name [CONTACT_790] :  Departme nt of Defense  Proposal Number: DM120101  
Investigational Device:   OkuStim®; a product of OkuVision 
Protocol Title:  Evaluation of the Effectiveness of Transcorneal Electrical 
Stimulation to Improve Visual Function Following Ocular 
Trauma  
Clinical Phase:  Pi[INVESTIGATOR_811046]:  To restore and rehabilitate vision loss as measured by [CONTACT_811065]. 
No. Study Sites: One 
Study Objectives:  • Evaluate the effectiveness of TES to improve visual function 
in adults with visual defects as a result of ophthalmic trauma 
with incidence greater than or equal to 3 months. 
 
• Evaluate the effectiveness of TES to improve visual function 
in adults with NAION or CIS/MS , a model of damage to 
optic nerve axons subsequent to trauma.  
Study Design: A prospective, randomized, SHAM- controlled clinical trial 
evaluating the efficacy in subjects with ophthalmic trauma , Non -
arteritic Anterior Ischemic Optic Neuropathy (NAION) , or Multiple 
Sclerosis (MS) /Clinically  Isolated Syndrome (CIS). 
Subject Population: The study population will consist of adults [ADDRESS_1121895] experienced:  
• Ophthalmic trauma ( w/ incidence greater than 3  months 
prior to recruitment).  
            OR 
• Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) 
(w/ incidence greater than 6 months prior to recruitment). 
                         OR 
• Multiple Sclerosis (MS) or Clinically Isolated Syndrome 
(CIS) (w/ diagnosis and/or incidence of acute vision loss greater than 6 months prior to recruitment). 
And who have chosen to participate in this clinical study as 
evidenced by [CONTACT_811066]. 
Inclusion Criteria Inclusion Criteria:  
• Age ≥ eighteen (18) years 
• Ophthalmic trauma ( w/ incidence greater than 3  months 
prior to recruitment ).  
Page 4 of 84   Name [CONTACT_790] :  Departme nt of Defense  Proposal Number: DM120101  
Investigational Device:   OkuStim®; a product of OkuVision 
OR 
• Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) 
(w/ incidence greater than 6 months prior to recruitment). 
OR 
• Multiple Sclerosis (MS) or Clinically Isolated Syndrome 
(CIS) (w/ diagnosis and/or incidence of acute vision loss 
greater than 6 months p rior to recruitment).  
• Willing and able to give written informed consent. 
• Able to perform study during full time period of one year. 
 
Exclusion Criteria Exclusion Criteria:  
•    Any other significant ophthalmologic disease or condition 
with relevant effect u pon visual function as evaluated by 
[CONTACT_2792] (e.g. glaucoma, retinal degeneration, 
proliferative diabetic retinopathy, exudative age -related 
macular degeneration (AMD), retinal detachment,  
+/- six diopters of myopia). 
•    Vision better than 20/4 0. 
• Amblyopia in affected eye, reported earlier in life.  
• Participation in any other interventional clinical trial.  
• Women who are pregnant OR women with childbearing 
potential and who are unwilling to use medically acceptable 
means of birth control for study duration OR  women 
unwilling to perform a pregnancy test at study entry/screening  and at each treatment visit prior to 
treatment . 
• Inability to detect phosphenes at the time of threshold detection 
• History of epi[INVESTIGATOR_811047]/or prescribed to anti-epi[INVESTIGATOR_811048] -seizure medication .  
 
Treatment Outline:  Follow ing recruitment and screening , subjects will be randomized in 
either the treatment or SHAM group.  The treatment group will 
undergo electrical stimulation once a week for six weeks.  Subjects in the S HAM group will wear the OkuSpex® once a week for six 
weeks,  but will not experience the electrical stimulation.  After six 
weeks of the SHAM treatment, these subjects will undergo genuine 
TES electrical stimulation once a week for six weeks.  
Prima ry Effectiveness 
Endpoint: The primary outcomes are change in high -contrast LogMar VA and 
change in low -contrast LogMar VA from baseline (week 1) to initial 
post treatment (week 8). Each outcome will be modeled separately. 
Page 5 of 84   Name [CONTACT_790] :  Departme nt of Defense  Proposal Number: DM120101  
Investigational Device:   OkuStim®; a product of OkuVision 
Secondary 
Effectiveness Endpoint: Secondary outcomes are change in visual field mean deviation, contrast sensitivity, VEP results (peak latency, amplitude of the p100 wave),  IOP, SD- OCT nerve thickness, NEI -VFQ-25 total 
score and subscores, and SDMT total score  
Safety Endpoints: • The ap pearance or development of corneal abrasion.  
• The appearance or development of argyrosis.  
Study Duration: Four Years 
 
Page 6 of 84    
STUDY OVERVIEW  
 
 
Treatment Group Schedule  
Visit:  1 2-7 8 9 10 
Time Frame  Week 1  Week 2 -7 Week 8  Week 19  Week 33  
 Consent  
Pre-treatment 
testing  Intervention/ 
Treatment  1-Week Post -
Treatment  
Testing  12-Week Post -
Treatment 
Testing  26-Week Post -
Treatment 
Testing  
Complete Ocular Exam  X  X X X 
Visual Acuity ETDRS  
Sloan Low Contrast 
Sensitivity  X 6X X X X 
Visual Field 24 -2, Static  X (3 pe r eye)  X X X  
Visual Evoked Potential  X  X  X 
SD-OCT X  X  X 
Fundus Photography  X  X  X 
NEI-VFQ -[ADDRESS_1121896]  X 6X    
Page 7 of 84    
Sham  Group Schedule  
Visit:  [ADDRESS_1121897] 
Sensitivity  X 6X X 6X X X X 
Visual Field 24 -
2, Static  X 
 (3 per eye)   X  X X X  
Visual Evoked 
Potential  X  X  X  X 
SD-OCT X  X  X  X 
Fundus 
Photography  X  X  X  X 
NEI-VFQ -[ADDRESS_1121898] OF  ABBREVIATIONS  
 
 
Term   
Definition  
AE Adverse Event  
AIC Akaike Information Criterion  
AION  Anterior Ischemic Optic Neuropathy  
AMD  Age-Related Macular Degeneration  
ARED  Age Related Eye Disease Study  
BcL-2 B-Cell Lymphoma -2  
BDNF  Brain Derived Neurotro phic Factor  
BIC Bayesian Information Criterion  
CAT  Computer Axial Tomography  
CDC  Centers for Disease Control and Prevention  
CDMRP  Congressionally Directed Medical Research Program  
CE MARK  Conformité Européenne (European Conformity)  
CI Confidence In terval  
CIS Clinically Isolated Syndrome  
CLIA  Clinical Laboratory Improvement Amendments  
CNTF  Ciliary Neurotrophic Factor  
COT  Combat Ocular Trauma  
CPEC  Cataract and Primary Eye Care  
DME  Diabetic Macular Edema  
DOD  Department of Defense  
DRCR  Diabetes  Retinopathy Clinical Research Network  
Page [ADDRESS_1121899] Growth Factor -2 
HcG  Human Chorionic Gonadotropin  
H&E  Hematoxylin and Eosin  
HELP  Heparin -induced Extracorporeal  LDL/fibrinogen Precipi[INVESTIGATOR_811049]-[ADDRESS_1121900]  Optical Coherence Tomagraphy  
OEF  Operation Enduring Freedom  
OIF Operation Iraqi Freedom  
OSS Open Source Software  
PI [INVESTIGATOR_811050]' Training Corps  
RP Retinitis Pi[INVESTIGATOR_811051]-OCT  Spectral Domain Optical Coherence Tomography  
SDMT  Symbol Digit Modalities Test  
SOW  Scope of Work  
SPSS  Statistical Package for Social Science  
TBI Traumatic Brain Injury  
TENS  Transcutaneous Electrical Nerve Stimulation  
TES Transcorneal Electrical Stimulation  
TJU Thomas Jefferson University  
TON  Traumatic Optic Neuropathy  
[LOCATION_003]MRMC  [LOCATION_002] Army Medical Research and Materiel Command  
VA Visual Acuity  
Page [ADDRESS_1121901] OF ABBREVIATIONS  ....................................................................................................................... 8 
1. Introduction ............................................................................................................................................. 17 
1.1 Name [CONTACT_811118] .......................................................................................................... 17 
1.2 Disease Background ......................................................................................................................... 17 
Figure 1a: Hematoxylin and eosin stain of a normal retina. ........................................................... 18 
Figure 1b:  Measurement of the peripapi[INVESTIGATOR_69349].  ......................... 18 
1.3 Mechanism of Action ....................................................................................................................... 18 
Figure 2: Photo transduction of vision and electrical response from light ...................................... 19 
1.4 Device Overview  .............................................................................................................................. 19 
Figure 3: Okuvision®- Stimulation Set  ........................................................................................... 20 
1.4.1 The OkuStim ® Device  .............................................................................................................. 20 
1.4.2 Key Components of the Device................................................................................................. 20 
Figure 4: Key pad buttons on OkuStim® device  ............................................................................ 21 
Figure 5: Adjusting OkuSpex® glasses .  ........................................................................................ 21 
Figure 6: OkuEl® Electrode  ........................................................................................................... 21 
1.5 Preclinical Studies ............................................................................................................................ 22 
1.6 Clinical Studies ................................................................................................................................. 22 1.7 Purpose of the Clinic al Study  ........................................................................................................... 23 
1.8 Duration of the Study ....................................................................................................................... 23 
2. STUDY RATIONALE AND OBJECTIVES  ......................................................................................... 23 
2.1 Study Rationale................................................................................................................................. 23 2.2 Study Objectives ............................................................................................................................... 24 
3. STUDY DESIGN  .................................................................................................................................... 25 
3.1 Type and Design of Study ................................................................................................................ 25 3.2 Study Treatments  .............................................................................................................................. 25 
3.3 Duration of Study and Rationale ...................................................................................................... 25  
3.4 Prima r
y Effectiveness Endpoints ...................................................................................................... 26 
3.4.1 Endpoints 1 and 2 ...................................................................................................................... 26 
Page 13 of 84   3.5 Secondary Effectiveness Endpoint ................................................................................................... 26 
3.5.1 Endpoints ................................................................................................................................... 26 
3.6 Additional Effectiveness Endpoint ................................................................................................... 26 
3.7 Primary Safety Endpoints ................................................................................................................. 26 
4. STUDY POPULATION  ......................................................................................................................... 26 
4.1 Informed Consent ............................................................................................................................. 27 
4.2 Eligibility Criteria  ............................................................................................................................. 28 
4.2.1. Inclusion Criteria ...................................................................................................................... 28 
Table 4.2.1: Inclusion Criteria for  Subject Enrollment ................................................................... 28 
4.2.2 Exclusion Criteria ...................................................................................................................... 29 
Table 4.2.2: Exclusion Criteria for Subject Enrollment .................................................................. 29 
5. STUDY PROCEDURES  ........................................................................................................................ 29 
5.1 Schedule of Assessments at Each Study Visit .................................................................................. 30 
Table 5.1.1a: Testing Schedule: Initial Treatment-Randomized Group ......................................... 30 
Table 5.1.1b: Testing Schedule: Initial SHAM-Randomized Group .............................................. 31 
5.2 Recruiting/Pre- screening  .................................................................................................................. 32 
5.3 Screen Failures ................................................................................................................................. 33 5.4 Screening and/or Baseline Evaluation .............................................................................................. 33 
5.4.1 Complete Ocular Exam ............................................................................................................. 33 5.4.2 Visual Acuity - Early Treatment Diabetic Retinopathy Study (ETDRS)  .................................. [ADDRESS_1121902] ................................................................................................... 34 
5.4.4 National Eye Institute Visual Functioning Questionnaire (NEI- VFQ -25) ................................ 34 
5.4.5 Visual Field 24- 2, Static  ............................................................................................................ 35 
5.4.6 Spectral-Domain Optical Coherence Tomography ................................................................... 35 5.4.7 Fundus Photography .................................................................................................................. 35 
5.4.8 External Ocular Photography .................................................................................................... 35 5.4.9 Visual Evoked Potential ............................................................................................................ 36 
5.5 Tr eatment  .......................................................................................................................................... 36 
5.6 Administering TES through the OkuStim® device .......................................................................... 37 
Figure 7: Position of the skink electrode on the temple .................................................................. 37 Fig
ure 8:  Adjustment of the bars on the OkuSpex® glasses  .......................................................... 38 
Figure 9:  OkuEl® electrode ........................................................................................................... 39 Figure 10: Pull OkuEl® filament over both bars to position within slit ......................................... 39 Figure 11: OkuSpex® shown with two OkuEl® ............................................................................ 40 
Page 14 of 84   Figure 12: OkuSpex® glasses in position with correctly adjusted bars .......................................... 40 
Figure 13:  OkuEl® electrode on eye, contact[CONTACT_811067] ........................ 41 
Figure 14: Plug of OkuSpex® Sitting in OkuStim® female connector .......................................... 41 Figure 15: USB port for physician and Mini USB stick port (right side)  ....................................... [ADDRESS_1121903] treatment (Week 15) ......................................................................................... [ADDRESS_1121904] treatment (Week 26)  .................................................................................. [ADDRESS_1121905] treatment (Week 40) .......................................................................................... 43 
5.8 Withdrawal Criteria and Procedures ................................................................................................. 43 
5.9 Protocol Deviations .......................................................................................................................... 43 
5.10 End of Study (Completion) ............................................................................................................. [ADDRESS_1121906] Sensitivity ................................................................................................................... 45 6.2.2 Visual field mean de viation  ....................................................................................................... 46 
6.2.3 Visual Evoked Potential ............................................................................................................ 46 
6.2.4 Intraocular Pressure Measurement (IOP)  .................................................................................. 46 
6.2.5 Spectral Domain - Optical Coherence Tomography ................................................................. 47 6.2.6 National Eye Institute Visual Functioning Questionnaire (NEI- VFQ -25) ................................ [ADDRESS_1121907] ................................................................................................... 47 
6.3 Safety Variables ................................................................................................................................ 48 
7. STATISTICAL ANALYSIS................................................................................................................... 48 
7.1 Primary Effectiveness Endpoint ....................................................................................................... 48 7.2 Secondary Effectiveness Endpoints .................................................................................................. 49 
7.2.1 Additional Effectiveness Endpoints .......................................................................................... 49 
7.2.2Long- term Changes .................................................................................................................... 49 
7.3 Sample Size ...................................................................................................................................... 49 
7.4 Datasets ............................................................................................................................................. 50 
7.4.1 Full Data Set .............................................................................................................................. 50  
7.4.2 Per-prot
ocol Data Set ................................................................................................................ 50 
7.4.3 Missing Data ............................................................................................................................. 50 
7.5 Primary Hypothesis .......................................................................................................................... 50 
Page 15 of 84   7.6 Secondary Hypothesis ...................................................................................................................... 50 
7.7 Analysis of Safety ............................................................................................................................. 51 
8. RESTRICTIONS  .................................................................................................................................... 51 
8.1 Prohibited Medications ..................................................................................................................... 51 
8.2 Other Restrictions ............................................................................................................................. 51 
9. EVALUATION OF ADVERSE EVENTS  ............................................................................................. 51 
9.1 Definitions ........................................................................................................................................ 51 9.2 Relationship to the Investigational Device ....................................................................................... 51 
Table 9.2 Possible Relationship Between Adverse Events and Inv estigational Device  ................. 51 
9.3 Unanticipated Adverse Device Effects (Events)  .............................................................................. 52 
9.4 Serious Adverse Events .................................................................................................................... 52 9.5 Reporting Requirements for Serious Adverse Events ...................................................................... 52 
9.6 Severity ............................................................................................................................................. 53 9.7 Deaths ............................................................................................................................................... 53 9.8 Pre-existing Conditions .................................................................................................................... 53 
9.9 Clinical Laboratory Changes ............................................................................................................ 53 9.10 Independent Study Oversight (Data Safety Monitoring Board) ..................................................... [ADDRESS_1121908]/Ethics Committee  ............................................................................... 56  
12.3 Confident
iality of Patient Records .................................................................................................. 57 
13. REPORTS AND RECORDS MANAGEMENT  .................................................................................. 57 
13.1 Investigator Records ....................................................................................................................... 57 
Page 16 of 84   13.2 Investigator Reports ........................................................................................................................ 58 
13.3 Data Collection ............................................................................................................................... 59 
13.4 Source Documents .......................................................................................................................... 59 
13.5 Records Retention at the Study Site ............................................................................................... 59 
14. MONITORING PROCEDURES  .......................................................................................................... 59 
14.1 Monitoring ...................................................................................................................................... 59 
14.2 Pre-Study Monitoring Procedures .................................................................................................. 60 
14.2.1 Selection of Monitors .............................................................................................................. 60 
14.2.2Clinical Investigators ................................................................................................................ 60 
14.3 Pre- Investigation Visit  .................................................................................................................... 60 
14.4 Periodic Monitoring Visits  ............................................................................................................. 61 
14.5 Frequency of Monitoring Visits...................................................................................................... 61 14.6 Study Termination .......................................................................................................................... 61 14.7 Reports of Monitoring Visits .......................................................................................................... 61 
14.8 Additional Auditing ........................................................................................................................ 62 
15. CONFIDENTIALITY ........................................................................................................................... 62 16. AMENDMENT POLICY ..................................................................................................................... 62 STUDY SITES AND INVESTIGATORS  ................................................................................................. 63 
REFERENCES  ........................................................................................................................................... 64 
Attachment 1: .............................................................................................................................................. 67 Attachment 2: .............................................................................................................................................. 78 Attachment 3: .............................................................................................................................................. 79 Attachment 4: .............................................................................................................................................. 81 Attachment 5: .............................................................................................................................................. 83 
  
 
Page 17 of 84    
Evaluation of the Effectiveness of Transcorneal Electrical Stimulatio n to Improve Visual 
Function Following Ocular Trauma 
1. Introduction  
1.1 Name [CONTACT_811119] [CONTACT_811068] ® Stimulation Set manufactured by [CONTACT_811069], Reutlingen, [LOCATION_013], is a 
potentially effective therapy for the restoration and rehabilitation of vision loss as measured by [CONTACT_811070]: patients with ocular 
trauma , patient s with Non -arteriti c Anterior Ischemic Optic Neuropathy (NAION), and patients 
with Multiple Sclerosis (MS) or Clinically Isolated Syndrome (CIS).  
 The Okuvision® Stimulation Set is currently marketed outside the [LOCATION_002] under the 
European Medical Device Directive as a Class II  a device for patients with degenerative retinal 
diseases.  
1.2 Disease Background 
Combat ocular trauma (COT), defined as an injury to the eye and/or neuro-ophthalmological 
pathways, has almost doubled from 8% of all injuries during the Vietnam War to approximately 
13% during Operation Iraqi Freedom (OIF) (1,2). Blasts to the head, face and neck caused the 
majority (85%) of these injuries (3-5).  Such COT injuries often result in severe vision loss and visual dysfunction (6).  In fact, COT in these soldiers doubles the risk of visual impairment and poor visual outcomes, with 33% of eyes worse than best-corrected visual acuity (VA) of 20/200 (3). In addition, approximately 20% of all military personnel deployed in Iraq and Afghanistan 
suffered from tr aumatic brain injury (TBI) (3,7,8).  The majority of the military personnel 
diagnosed with TBI also have visual dysfunction characterized by [CONTACT_811071], strabismus, 
pursuit and saccade insufficiencies, accommodative and convergence insufficiencies,  and 
diplopia (8). In addition, COT often results in injury to the retina and optic nerve, traumatic optic 
neuropathies (TON) and retinopathies; neither of which is  amenable to medical or surgical 
therapi[INVESTIGATOR_014]. Although, repair or regeneration of injured opti c nerves and retinas is impossible, the 
anatomy and physiology of these structures has been very well understood for decades (Figures 
1a, 1b).  However only recently have clinicians been able to assess in vivo, almost real -time 
pathological changes in the optic nerve and retina through spectral- domain optical coherence 
tomography (SD-OCT), multifocal electroretinography (mERG), and visually evoked potentials 
(VEPs).  
 
Page 18 of 84   
 
Figure 1a: Hematoxylin and eosin stain of a normal retina . 
 
 
 
 
Figure 1b:  Measurement  of the peripapi[INVESTIGATOR_69349].  
1.3 Mechanism of Action 
Page 19 of 84   The finely detailed, precise anatomy of the retina and optic nerve capture light impulses from the 
environment through a biochemical process and then transmit these images to the brain via 
electrical impulses conducted from the inner retina to the optic nerve and ultimately to the 
occipi[INVESTIGATOR_96067].  
In the human eye, three types of specialized  ganglion cells transmit electrical impulses to the 
brain. Among these three cell p opulations are rod and cone cells, which participate in the photo -
transduction step of light perception, along with other light  sensitive ganglion cells. It is a system 
whereby [CONTACT_811072][INVESTIGATOR_811052] (or one of its analogs) rearranges in resp onse to 
light, and this change in chemical structure fires electrical impulses to the brain which in turn interprets the incoming impulses as a v isual image as shown in Figure 2.  
 
 
 
  
 
 
 
 
 
 
 
Figure 2 : Photo transduction of vision and electrical response from light  
 
Transcorneal Electrical Stimulation (TES) using the OkuStim ® device delivers electrical 
impulses to damaged and/or diseased photorecepter cells.  This electric stimulation of the retina 
may help to preserve VA and/or the visual field.   
1.4 Device Overview  
The manufacturer of the Okuvision® Stimulation Set, Okuvision GmbH is based in Reutlingen, 
[LOCATION_013].  The Okuvision® device is one of the first out -patient treatments for degenerative 
retinal diseases.  The Okuvision® Stimulation Set is a  batter y powered, electronic 
neurostimulator system consisting of the three components shown in Figure 3. 

Page 20 of 84   • OkuStim ®, a reusable battery -powered, electronic neurostimulator which delivers a 
pulse, biphasic square output with a pulse duration of one (1) millisecond at a frequency 
of 20Hz; 
• OkuEl ®, single- use, disposable, sterile electrode; and  
• OkuSpex®, glasses to properly position the OkuEl® electrode.   
 
 
Figure 3: Okuvision®- Stimulation Set  
1.4.1 The OkuStim ® Device  
A weak electrical  current is delivered by [CONTACT_100359] O kuStim ® device using the OkuE l® 
electrodes, which are held in place  via the OkuSpex® glasses.   The electrical output of 
the OkuStim ® device can  be adjusted by [CONTACT_811073]. The intensity of the electric stimulation will be evaluated and 
determined individually for each subject by [CONTACT_613763]. S ettings  for each subject  are 
stored on a Mini- USB -stick and on a computer to enable investigation of the therapy over 
time.  
After switching on the neurostimula tor, the subject’s retina will be stimulated through 
specific electrodes worn on the face with the predetermined intensity and time period.  
1.4.2 Key Components of the Device  
1.) OkuStim ® Device – The OkuStim ® Device is a hand held battery-powered 
neurost imulator.  As shown in Figure 4, the handheld device consists of a display screen 
an “On / Off / Stop” button, a “Pause” button, and a “Start” button.  The handheld device  
and unique computer software program  allows the technician to decrease or increase 
intensity as required by [CONTACT_31031].  It is  also equipped with acoustic signals 
indicating all substantial conditions of the device.  Signals can indicate normal or 
abnormal settings.  The p ower is provided by [CONTACT_811074].  
Page 21 of 84   
 
Figure 4 : Key pad buttons on OkuStim ® device  
2.) OkuSpex® – The glasses called OkuSpex ® are used as a holder for the OkuEl® 
electrodes.  The bars on the frame can be adjusted horizontally and vertically to fit the 
subject’s facial contours.  Figure 5 highlights the adjustment mechanism.   
    
 Figure 5 : Adjusting OkuSpex ® glasses .   
 
3.)  OkuEl ® – The OkuEl ® electrode is comprised of a silver threaded filament.  The 
electrode is connected to the glasses and the filament is placed on  the subject’s 
conjunctiva.   Figure 6 provides a pi[INVESTIGATOR_811053].  
 
Figure 6: OkuEl ® Electrode 
 
 
Page [ADDRESS_1121909] studies to show beneficial effects of electrical stimulation on the retina was that 
conducted by [CONTACT_811075] a l. using the Royal College of Surgeons (RCS)  rat strain which serves 
as a human model for retinitis pi[INVESTIGATOR_1802] (RP) (18,19). They demonstrated survival of ganglion 
cells after optic nerve injury both in vivo and in vitro . The positive results indicated tha t TES, an 
easily administered treatment via a novel, class three device ( OkuStim ®) developed by 
[CONTACT_811076], prolonged the survival of injured photoreceptor cells. These studies also specified that vision improved due to the effects ascribed to the stimulation on 
various growth factors and regulatory molecules on retina including insulin-like growth factor 
(IGF -1), enhanced release of fibroblast growth factor (FGF2) and B- cell lymphoma 2  (Bcl -2) 
protein, ciliary neurotrophic factor (CNTF), and brain derived neurotrophic factor (BDNF) 
(18,20,21). In most of the above studies, electrical currents have been applied in trans-corneal 
fashion using contact [CONTACT_811077], hence the term TES. In addition, a systematic analysis of the neuro -protective effect of different stimulus parameters of TES on axotomized retinal 
ganglion cells (RGCs) of the RCS  rat showed that TES promoted survival of RGCs and the 
degree of neuroprotection depended on pulse duration (18).   
1.6 Clinical Studies 
The Food and Drug Administration ( FDA) describes Transcutaneous Electrical Nerve Stimulation 
(TENS ) as the use of an electric current to stimulate a target neural tissue for therapeutic purposes 
(10). TENS has been evaluated by [CONTACT_4760] a safe, non -invasive procedure and can offer 
subjects effective alternative treatments to pain alleviation. In support of its treatment efficacy 
and safety, over one-hundred published clinical reports exist regarding the use of TENS for 
various types of conditions, such as low back pain, myofascial and arthritic pain, sympathetically mediated pain, bladder incontinence, neurogenic pain, and postsurgical pain (11). Furthermore, electrical stimulation of neural cells has been used for the treatment of many neurological disorders for several years. Such uses for electrical stimulation include therapy for spi[INVESTIGATOR_313447], simulators for subjects with Parkinson’s disease, cochlear implants for sensorineural hearing loss, and therapi[INVESTIGATOR_811054] ( 12-15). 
Therefor e, electrical stimulation of neural tissues has been accepted by [CONTACT_811078]. In addition, recent  reports show potential efficacy 
using trans-corneal electrical stimulation (TES) to imp rove visual function (16- 22). Therefore, the 
success of electrical stimulation in these neuro -degenerative disorders provides a reasonable 
rationale and signi ficant pre cedent to investigate its potential in disorders of the optic nerve and 
retina, which function via an integration of biochemical and electrical interactions.  
Recently, interest has been renewed by [CONTACT_811079] a small 
number of subjects with non- arteritic anterior ischemic optic neuropathy  (NAION)  and 
long-standing retinal artery occlusion (16,17).  In addition, interest has been raised by 
[CONTACT_811080] a sub -retinal implant can promote visual functions in areas 
distant from the implant which has been attributed to the release of neurotrophic and other 
growth factors (23 ).  
In 2011, one German study assessed the safety of TES and explored its efficacy on various 
subjective and objective parameters of visual functio n in patients with RP . All 24 recruited 
Page 23 of 84   subjects were able to complete the study; only two subjects reported minor complaints after 
receiving TES treatment and no subject reported serious adverse events. One patient reported a mild foreign body sensation and showed minor irritation of the conjunctiva after IOP measurement, which was attributed to a reaction against the anesthetic eye drops used 
in the study. Another patient experienced a foreign body sensation after one stimulation, 
which resolved itself af ter prescription of artificial tears twice hourly for 1 day ( 22).
  No 
other serious adverse events were reported. In addition, electrical stimulation via DTL electrodes was reported to be tolerated well, not only for threshold determinations with short current pulses but also for continuous stimulation for [ADDRESS_1121910] results were all within normal physiological 
ranges at all visits ( 22).
    
Numerous other clinical studies evaluating the safety  and efficacy of TES in humans and 
animals suffering from a diversity of various ocular pathologies (including retinitis 
pi[INVESTIGATOR_1802], branch retinal artery occlusion, neuropathy, etc), have shown the device to be 
safe, fast, and reliable, with minimal occur rence of adverse outcomes. No serious adverse 
events were reported in any of the above studies ( 16, 17, 29-31). There is no evidence that 
leads us to believe that the study, which uses TES to treat subjects suffering from ocular 
trauma, would present any m ore risk to subjects than other clinical studies of this nature, as 
we are implementing TES in a near-identical fashion as other published studies. Therefore, 
the most probable foreseeable risk in this study is a minor adverse ocular event occurring in subjects who receive TES treatment, such as a mild foreign body sensation or minor 
irritation. Subjects receiving the SHAM-treatment and study personnel giving the treatment 
should have no foreseeable treatment- related risks.  
1.[ADDRESS_1121911] clinical data to support the hypothesis that electrical 
stimulation using the OkuStim ® device will improve visual function.  The study protocol will 
support a premarket approval application .  
1.8 Duration of the Study  
The anticipated duration for this study is four years .  Enrollment is anticipated to require 
approximately 36 months. Treatment program and follow up will be 26 for initial treatment group 
and 40 weeks for Sham group .  
2. STUDY RATIONALE AND O BJECTIVES 
2.1 Study Rationale 
As discussed in the introduction, COT, defined as injury to the globe, periocular anatomy, or 
neurological pathways involved with VA or ocular motility during combat operations, has 
increased from 8% of all injuries during the Vietnam War to approximately 13% during OIF and 
Operation Enduring Freedom (OEF) (27, 28).  Such COT injuries ofte n result  in severe vision 
loss and visual dysfunction (6).  The majority of the military personnel diagnosed with TBI also have visual dysfunction, difficultly reading, strabismus, pursuit and saccade insufficiencies, 
accommodative and convergence insufficiencies, and diplopia (8). Although the frequency of 
COT may be greater than ocular trauma as a result of civilian injuries, the types of ocu lar injuries 
Page [ADDRESS_1121912] 
this treatment could also be used in other traumatic eye disorders (16). The pathogenesis and 
pathophysiology of NAION and MS/CIS represent an excellent clinical model of the vascular component of TON. Subjects with chronic visual defects resulting from NAION or MS/CIS are a 
model subgroup to study the effect of visual function using TES.   
The administration of TES, focused on restoration and rehabilitation of vision loss resulting from ophthalmic trauma, offers the potential to significantly impact military personnel. The present study will use a portable electronic system (OkuStim®) which delivers bi- phasic pulses in 
subjects with traumatic visual deficits. The bi- phasic pulse model is generated into a digital 
processor, and is based on a healthy eye's mERG response. The intensity, time duration and repetition rate are titrated and individualized to the subject’s threshold levels of response. Preliminary data from several studies have shown an improvement in subjects’ VA and visual fields, and increased B wave response in standard ERG tests when TES is applied in subjects with 
low vision (22, 29, 30, 31).   These and other researchers concluded that further studies with larger 
sample sizes and longer duration are needed to confirm findings and to define optimal stimulation parameters (29 -31).  
This clinical trial is  designed as an early phase feasibility study administering TES via a novel, 
safe, externally applied class three (3) device (OkuStim®) focusing on restoration and 
rehabilitation of vision loss resulting from ophthalmic trauma, NAION, or MS/CIS. The study offers potentially significant impact to military personnel because our study population will 
mirror those suffering from combat-related ophthalmic trauma and injuries.  
2.2 Study Objectives 
Wills Eye Hospi[INVESTIGATOR_307] (Philadelphia, Pe nnsylvania) will  coordinate a prospective, randomized, 
SHAM -controlled clinical trial evaluating the efficacy in subjects with ophthalmic trauma , 
NAION, and MS or CIS.  
The specific aims of the clinical trial are to:  
(1)   Evaluate the effectiveness of TE S to improve visual function in adults with visual 
defects as a result of ophthalmic trauma.  
(2)   Evaluate the effectiveness of TES to improve visual function in adults with NAION, 
or MS/CIS,  a model of damage to optic nerve axons subsequent to trauma. 
 
Primary  Hypothesis: As in the case of  central nervous system strokes, in which there is a central 
area of irreversible infarction and a border zone of tissue that has some normal anatomic structure 
but does not function (so called "ischemic penumbra,” akin to a state of hibernation), we postulate 
that some cells and axons of the optic nerve and retina are damaged by [CONTACT_811081]. We hypothesize that because vision is a physiological function uniting a biochemical pathw ay with an electrical signal that providing a controlled, well -defined, safe 
Page 25 of 84   electrical stimulus has the potential to restore function to photoreceptors, glial cells, and axons 
that are not irreversibly damaged.  
 
Secondary  Hypothesis:  Similarly, we believe  that electrical stimulation of optic nerves and 
retinas damaged by [CONTACT_278066], ischemia, and multiple sclerosis may regain some function of the 
afferent visual system as defined by [CONTACT_811082].  
3. STUDY DESIGN 
3.1 Type and Design of Study 
Wills Eye Hospi[INVESTIGATOR_17399] l (Philadelphia, Pennsylvania) will conduct  a prospective, randomized, SHAM-
controlled clinical trial evaluating the efficacy in patients with ophthalmic trauma, NAION, and 
MS or CIS . Forty-two (n=42) subjects with visual defects due to  ophthalmic trauma, up to 
seventy -five  (n=75 ) subjects diagnosed with NAION, and forty-two (n=42) subjects diagnosed 
with MS or CIS will be recruited from the Wills Eye Neuro -Ophthalmology, Retina, Cataract and 
Primary Eye Care (CPEC), and Oculoplastic and Orbital Surgery Services. Subjects will also be identified as they present in the Wills Eye Emergency Room. Three groups of subjects will be randomized in a 2:1 ratio as follows: 28 ophthalmic trauma subjects, 50 NAION subjects, and 28 
MS or CIS subjects will be included in the TES treatment group.  Subjects in the SHAM-
intervention (TES) group will include [ADDRESS_1121913] will undergo screening for eligibility in the study.  If eligible for the study, subjects  will be randomized in a 2:[ADDRESS_1121914] will be placed in the SHAM group.   
 Subjects in the treatment group will undergo TES once a week for six weeks.  Subjects in the 
SHAM group will wear the OkuStim ® device, but will receive no electrical stimulation.  After 
the initial six weeks, th e SHAM group will undergo the TES treatment once a week for six 
weeks.  
 3.[ADDRESS_1121915] treatment ( 40 weeks ). 
3.4 Primary Effectiveness Endpoints  
3.4.1 Endpoints 1 and 2  
The study’s main goal is to estimate the effect of treatment for all study outcomes; it will  
also conduct two formal hypotheses tests for the primary outcomes. The primary 
outcomes are change in high -contrast LogMar VA and change in low -contrast LogMar 
VA from baseline (week 1) to initi al post treatment (week 8).   Each outcome will be 
modeled separately.   Since this is an exploratory study with no past data available, no 
endpoint will be defined for high or low contrast visual acuity.  The study compares the 
patients performance (number of letters seen on the high contrast and low contrast acuity 
charts) after treatment to the patient's own baseline prior to treatment.     
3.[ADDRESS_1121916] sensitivity, VEP 
results (peak latency, amplitude of the p100 wave),  IOP, SD -OCT nerve thickness, NEI -
VFQ -25 total score and subscores, and SDMT total score. The study will use a similar 
approach for the primary efficacy analysis. For those outcomes measured only at weeks 1 
and 8, measurement  will use a heterogenous compound symmetric covariance structure. 
Again, the study  will estimate the average change from baseline to week 8 for all three  
arms and the difference in change between arms.  
3.6 Additional Effectiveness Endpoint 
Long -term Changes 
Using data from all subjects, we will estimate the long -term effects of treatment. We will include 
all available data from the initial Treatment-Randomized group and all data from visits 8-17 from 
the initial SHAM -Randomized group. We will again use mixed effects linear regression to model 
the change in outcomes over time. Fixed effects will include time (relative to pre- treatment time) 
and randomization assignment (to control for possible period effects). We w ill use linear contrasts 
to estimate the change from post- treatment to week twelve  and post- treatment to [ADDRESS_1121917] of the presence of silver 
particles/ions or any discoloration process. Should the subject have an abrasion or the presence of discoloration during the physical exam, the subject will be notified immediately.  
4. STUDY POPULATION  
Page [ADDRESS_1121918] experienced:  
●  Ophthalmic trauma (w/ incidence  greater than or equal to  3 months prior to recruitment)  
     OR  
● Multiple Sclerosis (MS) or Clinically  Isolated Syndrome (CIS) (w/ diagnosis or incidence 
of acute vision loss greater than or equal to 6 months prior to recruitment) 
     OR   
● Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) (w/ incidence gr eater than or 
equal to 6 months prior to recruitment) 
and who have chosen to participate in this clinical study as evidenced  by [CONTACT_811083]. 
4.1 Informed Consent 
Written informed consent will be obtained from all subjects  (or their guardian or legal 
representative) before any study related procedures (including any pre- treatment screening 
procedures) are performed.  A copy of a sample informed consent document is provided in Attachment 1.  Investigators may discuss the availability of the study and the possibility for entry with a potential subject without first obtaining consent.  Informed consent must be obtained and 
documented prior to initiation of any procedures that are performed solely for the purpose of 
determining eligibility for research.  When this is done in anticipation of, or in preparation for, 
the research, it is considered to be part of the investigational study.  
The investigators have both ethical and legal responsibility to ensure that each subject being 
considered for inclusion in this study is given a full explanation of the protocol.  This should be documented on a written informed consent form that should be approved by [CONTACT_811084].  Each informed consent form should include the elements 
required by [CONTACT_235794] [ADDRESS_1121919]'s chart.  
  
Page [ADDRESS_1121920] also demonstrate acceptable proof of age of eighteen (18) years or 
older. Furthermore, subjects must present with ophthalmic trauma, diagnosis of MS or CIS, 
or a diagnosis of NAION.  
Table 4 .2.1: Inclusion Criteria for Subject Enrollment  
 Inclusion Criteria:  
• Age ≥ eighteen (18) years 
• Ophthalmic t rauma (w/ incidence greater than or equal to  3 months prior to 
recruitmen t).  
 OR 
• Multiple Sclerosis (MS) or Clinically Isolated Syndrome (CIS)  
 OR  
• Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) (w/ incidence greater than 
6 months prior to recruitment). 
• Willing and able to give written informed consent. 
• Able to perform study during full time period of one year. 
 
Page 29 of 84    
4.2.2 Exclusion Criteria 
For exclusion, subjects may satisfy any of the four specific exclusion criteria listed in Table 
4.2.2 OR be unable to satisfy any one of the designated inclusion criteria. Women an d 
minorities will be eligible to participate in the clinical trial.  
Table 4.2. 2: Exclusion Criteria for Subject Enrollment  
 
5. STUDY PROCEDURES  
Upon completion of the Informed Consent Form, subjects will be randomized in a 2:1 ratio into either the treatm ent group or the SHAM group.  Subjects in the TES treatment groups will receive 
TES from the OkuStim® device for [ADDRESS_1121921] the TES device placed over their eye each week for 30 minutes; 
however, electrical stimulation will not be received. These subjects will then receive TES from 
the OkuStim® device for 30 minutes per week for 6 consecutive weeks.  All subjects will undergo 
electrically evoked phosphene (EEP) testing to determine their stimulation threshold for the OkuStim® device. Stimulation threshold is defined as the frequency when subjects initially sense electrically evoked phosphenes. They will then receive treatment from the OkuStim® device at 
150% level threshold according to t heir unique threshold readings at each treatment.  
Evaluation methods for all subjects during the study (including the SHAM group) will consist o f 
complete ocular exams, VA testing (ETDRS and contrast sensitivity), visual field (VF; 24 -2, 
static), VEP, fundus photography, external photography and SD -OCT . All subjects will be tested 
at baseline and will receive additional testing according to the Testing Schedules shown in Table 
5.1.1a and 5.1.1b. Subjects in the intervention group will be re- tested after 6 w eeks of treatment 
(week 8) and at 12 weeks (week 19), and at 6 -month follow-up (week 33) to determine if 
improvements in visual function have been maintained (Table 5.1.1a ). Quality of life evaluation Exclusion Criteria:  
• Any other significant ophthalmologic disease or condition with relevant effect upon visual function as evaluated by [CONTACT_2792] (e.g. glaucoma, retinal degeneration, proliferative diabetic retinopathy, exudative age -related macular degeneration (AMD), retinal detachment,  
+/- six diopters of myopia). 
• Vision better than or equal to 20/40. 
• Amblyopia in affected eye, reported earlier in life.  
• Participation in any other interventional cl inical trial . 
• Women who are pregnant OR women with childbearing potential and who are unwilling to 
use medically acceptable means of birth control for study duration OR women unwilling to 
perform a pregnancy test at study entry/screening  and at each treatm ent visit prior to 
treatment.  
• Inability to detect phosphenes during threshold detection. 
• History of epi[INVESTIGATOR_811047]/or prescribed to anti- epi[INVESTIGATOR_811048] -seizure medication.  
Page [ADDRESS_1121922]- treatment  
(week 8) , 12-weeks post- treatment (week 19) and 6-month post -treatment  (week 33 ). Cognitive 
function evaluation via the SDMT will also be administered to all subjects at baseline, [ADDRESS_1121923]- treatment (week 8) and at 6-month post- treatment (week 33).  
5.[ADDRESS_1121924] screening and baseline evaluations, treatment plan and follow -up. 
Table 5.1.1a: Testing Schedule: Initial Treatment -Randomized Group  
Visit:  1 2-7 8 9 10 
Time Frame  Week 1  Week 2 -7 Week 8  Week 19  Week 33  
 Consent  
Pre-treatment 
testing  Intervention/ 
Treatment  1-Week Post -
Treatment  
Testing  12-Week Post -
Treatment 
Testing  26-Week Post -
Treatment 
Testing  
Complete Ocular Exam  X  X X X 
Visual Acuity ETDRS  
Sloan Low Contrast 
Sensitivity  X 6X X X X 
Visual Field 24 -2, Static  X (3 per eye )  X X X  
Visual Evoked Potential  X  X  X 
SD-OCT X  X  X 
Fundus Photography  X  X  X 
NEI-VFQ -[ADDRESS_1121925]  X 6X    
 
Subjects in the SHAM group will be re- tested after 6 -weeks of SHAM treatment (week 8) and 
after 6 -weeks of treatment (week 15) and at 12 -week follow -up (week 26) and 6- month follow -up 
(week 40) to determine if improvements in visual function have been m aintained (Table 5.1.1b).  
Page [ADDRESS_1121926]- SHAM treatment (week 
8), 1- week post-treatment (week 15), 12- week post- treatment  (week 26), and at 6-month post-
treatment ( week 40). Cognitive function evaluation via the SDMT will also be administered to all 
subjects at baseline, [ADDRESS_1121927]- SHAM treatment (week 8), [ADDRESS_1121928] -treatment (week 15) 
and at [ADDRESS_1121929]- treatment (week 40). Outcome measures will be based on the results of these 
tests as well as the rate of wound healing in acute trauma subjects and the ability to restore visual 
function in subjects with chronic visual impairment. Evaluation of visual outcomes will help develop possible predictive diagnostic criteria in adults with acute and visual deficits due to 
ophthalmic trauma or TBI. 
Table 5.1. 1b: Testing Schedule:  Initial S ham-Randomized Group  
Visit:  [ADDRESS_1121930] 
Sensitivity  X 6X X 6X X X X 
Visual Field 24 -
2, Static  X 
 (3 per eye)   X  X X X  
Visual Evoked 
Potential  X  X  X  X 
SD-OCT X  X  X  X 
Fundus 
Photography  X  X  X  X 
NEI-VFQ -[ADDRESS_1121931]  X 6X  6X    
 
 5.2 Recruiting/Pre-screening  
It is anticipated that recruiting will require a large pool of potential subjects. Therefore, recruiting 
will be broken out in three phases. Phase I (Years 1 -4) will focus on recruiting subjects within the 
Wills Eye Health System. Because this is a complex study with three different  study arms, an 
assessment will be made on which subjects are easily recruited and which subjects require more 
effort. After this assessment is made, we will reach out to develop collaborations with both 
Thomas Jefferson University Hospi[INVESTIGATOR_811055]. Phase II (Years 2 -4) will focus on recruiting subjects from Thomas Jefferson 
University Hospi[INVESTIGATOR_307]. Phase III (Years 2 -4) will focus on recruiting subjects from the Philadelphia 
and Wilmington Veterans Administration.  
 
Phase I – Wills Eye Health System  
We will recruit subjects from the various subspecialty departments of WEHS, as well as identify 
potential subjects that have been seen at the Wills Eye Emergency Roo m (ER) . We feel th at 
subjects that had been  patients in the Wills Eye ER and still require follow -up will provide an 
adequate, representative population. It is important to note that subjects will not be recruited while they are in the Emergency Room . The Wills Eye ER is the only 24 / [ADDRESS_1121932] is male between the ages of 18 -30 years old.   
 
Subjects will be recruited by [CONTACT_811085] (EMR) or be id entified by 
[CONTACT_811086].  If the research coordinator identifies a subject through EMR, he / she will 
then call the potential research subject.  A phone script has been developed and is attached.  
(Attachment 3)    
 For potential subjects  fitting the  inclusion/exclusion criteria  that are identified by [CONTACT_811087], the physician notifies the research coordinator that day. The research coordinator 
will meet with the potential subject to inform and educate him/her about the study.  In both 
instances, the subject then consents to the study with the physician after allowing sufficient time 
for the subject to read the consent form and ask questions.  
Subjects will also be recruited from a network of affiliated general ophthalmologists, neuro-
ophthalmology specialists, and retina specialists practicing in the Tri -State Area including those 
practicing at the Philadelphia Veterans Administration Hospi[INVESTIGATOR_811056], 
Page [ADDRESS_1121933] been diagnosed with NAION, or Multiple Sclerosis/ Clinically Isolated Syndrome  and will also specify that the study 
is for patients [ADDRESS_1121934] to patient/caregiver advertising will benefit recruitment and enrollment due 
the relatively small network of physicians and patients at Wills Eye Hospi[INVESTIGATOR_811057] , NAION , and MS/CIS. 
 
Phase II – Thomas Jefferson University Hospi[INVESTIGATOR_307] (Grant Years 2 -4) 
We plan t o utilize the collaboration between  Thomas Jefferson University Hospi[INVESTIGATOR_307] (TJUH).  
Wills Eye serves as th e Department of Ophthalmology for TJUH and its clinicians often see 
patients with head inju ries that present at the TJUH . Wills Eye will work with TJUH to recruit 
potential subjects.  
 Phase III – Philadelphia and Wilmington Veterans Administration (Grant Y ears 2 -4) 
Wills Eye will seek to include patients referred from the Philadelphia and Wilmington Veterans 
Administration Hospi[INVESTIGATOR_307].  The inclusion of the Philadelphia and Wilmington VA increases the 
potential of recruiting actual combat veterans.     
 5.[ADDRESS_1121935] is one from whom informed consent is obtained and is documented in 
writing (i.e. subject signs an informed consent form), but in whom treatment with the investigational device is not used because it is determined that  the subject does not meet all of the 
eligibility criteria, after signing the informed consent.  Screen failure subjects will not be counted 
towards the total enrollment of 126 subjects  
 5.4 Screening and/or Baseline Evaluation 
All subjects will receive th e following tests/evaluation at screening .  The results of the tests will 
serve as the data for the  baseline visit. No wash out of period from other treatments is required. 
5.4.[ADDRESS_1121936] 
assessing vision and ability to focus on and discern objects, as well as other tests and 
examinations relating to the eyes. The complete ocular exam will include an external examination, followed by [CONTACT_811088] (normal/abnormal), extraocular muscle motility (normal/abnormal), and measure of intraocular pressure (IOP). The 
complete ocular exam will also document the subjects’ current symptoms, health problems, 
Page 34 of 84   medications, and ocular co-morbidities.VA and v isual fields will be tested and are 
described below. 
5.4.2 Visual Acuity - Early Treatment Diabetic Retinopathy Study (ETDRS)  
VA is referred to as acuteness or clarity of vision , which is dependent on the sharpness of 
the retinal focus within the eye and the sensitivity of the interpretative capability of the 
brain. ETDRS acuity testing has become the worldwide standard for VA testing. It was 
developed to aid in evaluating the changes in vision following panretinal photocoag ulation 
in subjects with diabetic retinopathy. The ETDRS test incorporates specific design criteria to be more accurate than the Snellen or Sloan acuity tests. These include: 1) same number 
of letters per row (five letters per row) 2)  equal spacing of the rows on a log scale (the 
rows are separated by 0.1. log unit) 3) equal spacing of the letters on a log scale, and 4) 
individual rows balanced for letter difficulty. To prevent memorization, different versions of the ETDRS test chart are available. The three standard versions of the ETDRS chart are R, [ADDRESS_1121937]  
The SDMT, developed by [CONTACT_811089], PhD, is a simple, practical measure of information 
processing speed presented visually (33). The SDMT involves a simple substitution task. 
Using a reference key pairing unique symbols with numbers, the examinee has [ADDRESS_1121938] anyone, including those with motor disabilities 
or speech disorders.  
The SDMT been used in many disorders including head injury, stroke, brain tumor, reading 
difficulties, learning disorders, and dementia. Previous research in Subjects with MS has 
shown the SDMT to be reliable, sensitive, and strongly associated with brain magnetic 
resonance imaging (MRI) metrics (34 -38).  It has been proposed as a screening test for MS -
associated cognitive disorder and poor performance on the SDMT is associated with work disability (39,40). Unemployed subjects scored more poorly on several cognitive tests 
including the SDMT (41).  It was also the best predictor of numerous tests for behind the 
wheel driving performance in MS subjects (42). Data will be reported, quantified, and 
analyzed for each subject and changes over time will be tracked.  
5.4.4 National Eye Instit ute Visual Functioning Questionnaire (NEI- VFQ -25) 
The NEI -VFQ -[ADDRESS_1121939] possible scores are set at 0 and 100 points, respectively. Items within each subscale are averaged together to create 12 subscale scores (32). An 
Page 35 of 84   overall composite score will be calculated by [CONTACT_811090] -targeted subscale scores, 
excluding the general health rating question. The 12 sub- scales for the NEI -VFQ -25 
includes: 1) general health  2) general vision  3) ocular pain  4) near activities  5) distance 
activities  6) social functioning  7) mental health  8) role difficulties  9) dependency  10) driving  11) color vision, and  12) peripheral vision. The sub-scales [ADDRESS_1121940], low coherence near- infrared light is split into a probe and a reference 
beam.  The probe beam is directed at the retina while the reference beam is sent to a moving 
reference mirror.  The probe light beam is reflected from tissues accordin g to their distance, 
thickness, and refractive index. It is then combined with the beam reflected from the 
moving reference mirror.   When the path lengths of the two light beams coincide (known as 
constructive interference) it provides a measure of the dep th and reflectivity of the tissue 
that is analogous to an ultrasound A scan at a single point.  A computer then corrects for axial eye movement artifacts and constructs a two dimensional B mode image from successive longitudinal scans in the transverse direction.   A map of the tissue is then 
generated based on the different reflective properties of its components, resulting in a real -
time cross- sectional histological view of the tissue. SD -OCT is a relatively new non -
invasive imaging modality that uses reflected light in a manner analogous to the use of sound waves in ultrasonography to create high-resolution (10 micron) cross- sectional 
images of the vitreoretinal interface, retina and subretinal space, analogous to histological sections seen through a light  microscope. SD- OCT also gives quantitative information 
about the peripapi[INVESTIGATOR_69349], retinal architecture and structure. Data will be reported according to the change in the thickness of the retinal nerve fiber 
layer  and com pared to baseline measurements  
5.4.7 Fundus Photography  
A fundus camera or retinal camera is a specialized low power microscope with an attached camera designed to photograph the interior surface of the eye, including the retina, optic 
disc, macula, and posterior  pole (i.e. the fundus).  Fundus cameras are used by [CONTACT_795195] , 
ophthalmologists, and trained medical professionals for monitoring progression of a disease, diagnosis of a disease (combined with retinal angiography), or in screening 
programs, where the photos can be analyzed later.  Baseline fundus photograph data about the condition of the retina will be reported. 
5.4.[ADDRESS_1121941] will undergo a complete ocular examination, visual acuity 
(ETDRS), SDMT, NEI -VFQ -25, visual field  24-[ADDRESS_1121942], VEP, and slit lamp 
external photographs at the 3-month follow- up visit.  
Subjects will be randomized into either treatment- initial or SHAM -initial groups prior to their 
scheduled appoin tment. Trained technicians will administer OkuStim ® stimulation to subjects 
according to the treatment schedule.  Preservative -free, artificial tears (i.e. GenTeal) will be 
applied on the surface of the prior to the application of the OkuEl® fiber on the corneal surface at 
the time of each treatment . Additionally, the technicians will prepare and administer SHAM 
treatment for subjects, as appropria te. 
Subjects randomized to the treatment -initial group will undergo OkuStim® treatment once a 
week for a [ADDRESS_1121943] of 30 minutes of TES at 150 % 
threshold levels, which will be individualized for each subject using EEP testing. The settings 
will be stored on a password protected computer in order to provide consistent and appropriate 
stimulation across the six -week trial period and to enable investigation of the therapy over time.  
Subjects randomized to the SHAM -initial group will similarly be configured with an OkuStim® 
device, but the device in such case will provide no electric impulses and subjects will receive no 
TES. 30 minute se ssions will be held once a week  for six weeks. Following the 6- week SHAM 
trial, SHAM -initial subjects will return once a week for six additional weeks of genuine TES , 
during which they will receive full OkuStim ® stimulation according to the same schedule and 
procedure as the treatment -initial group. 
Page 37 of 84   Subjects in the intervention groups will r eceive TES from the OkuStim® device for [ADDRESS_1121944] the TES device 
placed over their eye each week for 30 minutes; however, electrical stimulation will not be received. After that, the  SHAM group will receive TES from the OkuStim® device for [ADDRESS_1121945] the potential of discoloration, presence of corneal abrasion and/or the presence of silver 
particles and/or ions . External photos will also be performed at the one week post treatment visit.  
All subjects will un dergo Electrically Evoked Phosphene (EEP) testing to determine their 
stimulation threshold for the OkuStim® device. Stimulation threshold is defined as the frequency 
when subjects initially sense electrically evoked phosphenes. They will then receive treat ment 
from the OkuStim® device at 150% level threshold according to their unique threshold readings. 
 
5.6 Administering TES through the OkuSti m® device 
After undergoing the EEP testing and prior to using the OkuStim® device on the subject, the 
skin electrod es must be placed on the subject. To ensure a good el ectric cont act zone , the skin 
on the subj ects’  temple  will be  cleaned with alcohol prep at each tr eatment and SHA M session, 
follow ed by [CONTACT_811091] . After cl eaning, a skin-el ectrode will be placed on to the 
temple  (Figure 7). Once a small amount of electrode gel is applied in the center of  the skin-
electrode, it can be placed on the t emple with gentle pressure. 
 
Figure 7: Position of the skink electrode on the temple  
 
After the  skin electr ode is applie d on the  subject, the technician will adjust the bar s on the frame 
of the O kuSpex® glasse s horizontally and ver tically to fit th e subjects’ facial contour s (Figure 
8). The thi ck screws at the j oints of the bars of the  Oku Spex® gl asses will be  slightly opene d in 
order to a djust the  vertical and horizonta l bars easily. The  Oku Spex® gla sses will th en be 
carefully put into position on the subj ect, while t he subject’s eyes ar e clos ed. The vertical bars 
will be ad juste d to a  suitable height, a nd if required, the nose pa d of the Oku Spex® gla sses can 
Page [ADDRESS_1121946] ed in height, a s well. The  horizonta l bars will be  position ed at the edge s of each eye , on 
top of the skin exac tly to the  right a nd left of e ach eye. 
 
 
Figure 8 :  Adjustment of the bars on the OkuSpe x® glasses 
 
Beca use only one eye wi ll be stimulated over the cour se of  this stu dy, only one OkuEl ® 
electrode and one skin el ectrode are required per s ubject per visit (Figure 9).  The OkuEl® 
electrod e will be placed onto t he bars of the OkuSpex® gla sses and ge ntly pulle d to slide  the 
filament into its final position within the  slit in the  horizonta l bar of the Oku Spex® gla sses 
(Figure 10 ). 
 
Page 39 of 84   
 
Figure 9:  OkuEl ® electrode  
 
 
Figure 10 : Pull OkuEl ® filament over both bars to position within slit  
 
 
Before  placement of t he O kuEl® el ectrode (Figure 11) preservative -free, artificial tears will be 
applied, then the horizonta l bars of the Oku Spex® glasses will be  carefully moved tow ards the 
eye. The O kuSpex® gla sses will be  correctly fitted to the  subj ect as soon as the OkuEl® 
filament cont acts the conjun ctiva underneath the  pupil without t ension. The  subj ect m ay no t 
sense the filament at all. The Oku Stim® technicia ns will th en take the Oku Spex® gla sses in 
hand and c arefully tighte n the  thick screws on the  joints of  the gla sses. 
 
 
Page 40 of 84   
 
Figure 11: OkuSpex ® shown with two OkuEl ® 
 
The Oku Spex® gla sses will th en be replaced on the subj ect, ensuring that the bars do not c ontact 
the eye s direc tly (Figure 12). Instead, the O kuEl® el ectrode-filament should cont act the 
conjunc tiva above the  lowe r eyelid. While putting on the OkuSp ex® glasse s, sm all mov ement of 
the eye s will facilit ate proper contact [CONTACT_811092]® elect rode-filament on th e eye. 
 
 
Figure  12: OkuSpex ® glasses in position with correctly adjusted bars  
 
The O kuEl® el ectrode-filament should be positione d directly above the  lower eye lid and 
below the pupil, cont acting the c onjunc tiva (Figure 13) . The skin-el ectrode a t the temple  
should be c onnec ted to the  snap-fastener on the cable of the Oku Stim® gla sses only after 
the device is turned O N. 
Page 41 of 84   
 
Figure 13:  OkuEl ® electrode on eye, contact[CONTACT_811093]® gla sses once the 
proper se tting of the horizonta l and v ertical bars has been ac hieved. The thi ck screws at the joints 
of the Oku Spex® gl asses should remain locked. Fo llowing  configuration of the Oku Spex® 
glasses and proper positioning of th e OkuEl® el ectrode-filaments on t he subj ect, the  Oku Spex® 
plug will be  positioned into the Oku Stim® female connector on the  upper si de of the OkuSti m® 
device (Figure 14) . The Mini-USB- stick will be  posi tioned within the  port of the OkuStim® 
device to p rovide the subj ects’ pers onal the rapy se ttings for transcorneal electrical stimula tion 
(Figure 15 ). 
 
  
Figure 1 4: Plug of OkuSpex ® Sitting in OkuStim® female connector  
Page 42 of 84     
  
                         Figure 1 5: USB port for physician and Mini USB stick port (right side)  
 
Whe n swit ched on by [CONTACT_941] t echnician, the Oku Stim® device will begin the therapy se ssion. The 
subject’s closed eye will be  stimul ated w ith weak electri cal puls es guide d to the  subj ect’s retina, 
according to the  setting d etermined by [CONTACT_811094] n (time and int ensity). S ubjects undergoing 
SHAM t reatment will not receive any electrical stimul ation. The  subject should remain 
stationary throughout the du ration of the 30-minute t reatment session.  
 
After 30 minute s of tre atment, either  the Oku Stim® device will self -terminate or the technician 
will terminate the stimulation by [CONTACT_811095] “S TOP” but ton on t he Oku Stim® dev ice and the 
treatment session will end. The plug of the O kuSpex® gla sses will be carefully removed. The 
subjects’ eyelid will be  opene d widely whi le carefully removing the O kuSpex® glasse s to allow 
for an ea sier withdrawal o f the O kuEl® el ectrode from the eye. The OkuEl® el ectrode and skin 
elect rode will th en be removed from the Oku Spex® gla sses and discarded. OkuEl ® elect rodes 
and skin-elect rodes are single-use medi cal devices; there are technical, func tional, and hy gienic 
r
easons for non- reusability.  
 
5.[ADDRESS_1121947] treatment.  
 
Subjects in the SHAM group will be re- tested af ter 6-weeks of SHAM treatment (week 8) and 
after 6 -weeks of treatment (week 15) and at the 12 -week follow-up (week 26) and 6-month 
follow-up (week 40) to determine if improvements in visual function have been maintained.   
5.7.[ADDRESS_1121948] treatment  (Week 15)  
Repeat all testing performed at baseline with the exception of repeating visual field.  Visual 
field testing is required to be performed once per eye. 
5.7.[ADDRESS_1121949] treatment (Week 26) 
Repeat complete ocular exam, visual acuity with ETDRS and Sloan low contrast sensitivity, 
visual field and NEI -VFQ -25. 
Page [ADDRESS_1121950] treatment  (Week 40)  
Repeat all testing performed at baseline with the exception of slit lamp external photography 
and of repeating visual field.  Visual field testing is r equired to be performed once per eye. 
 
 5.[ADDRESS_1121951]’s withdrawal should be documented on the appropriate case report.  The subject should 
undergo the recommended follow-up specified for the last study visit, including evaluation of disease signs and symptoms, unless contraindicated due t o a medical condition. Withdrawn 
subjects will not be replaced.  
5.[ADDRESS_1121952] requires a protocol deviation, based on the judgment of the investigator (or a responsible, appropriately trained professional designated 
by [CONTACT_093]). If the deviation from the protocol is necessary to protect the physical well -
being of a subject in an emergency, such protocol deviations must be reported to the sponsor and 
the reviewing IRB as soon as possible, but no later than [ADDRESS_1121953] continuation in the study. These 
discussions will be documented by [CONTACT_31376], and reviewed by [CONTACT_2037]. 
5.10 End of Study (Completion)  
All subjects who have signed an informed consent, except for screen failures, will be considered 
enrolled in the study. Subjects who complete the study duration will be considered to have completed the study. Any subject who does not return for scheduled follow- up visits will be 
contact[CONTACT_811096]. A new visit will 
be scheduled as soon as possible.  All subjects should be follo wed until completing the study 
follow- up or until study discontinuation (withdrawal) for other reasons. The reason for study 
discontinuation should be documented for each subject. For subjects who discontinue the study 
early, an effectiveness evaluation sh ould be conducted at the last study visit to document the signs 
and symptoms of the disease prior to study exit. 
6. EFFECTIVENESS AND SAFETY VARIABLES  
 6.[ADDRESS_1121954] ETDRS  Visual 
Acuity protocol. 
Page 44 of 84   Visual Acuity Chart:  Modified Bailey -Lovie:   The ETDRS visual acuity charts 1 and 2 are 
used for standardized measurement of visual acuity.  Acuity testing of all subjects, regardless 
of visual acuity, begins at four meters.  Two ETDRS Visual Acuity Charts are used for the 
measurement of visual acuity, each with a different letter sequence.   The right eye will always 
be tested with Chart 1 and the left eye with Chart 2. 
 
Illumination of Visual Acuity Charts and Room:  The light box will  be hung on the wall or 
placed on a stand at a height such that the top of the 3rd row of letters (0.8 LogMAR) is 49 + 
2 inches (124.5 + 5.1 cm) from the floor.  Room lighting should be approximately [ADDRESS_1121955]-Corrected Visual Acuity Measurements: The right eye is tested first and then the left 
eye.  The subject is seated 4.[ADDRESS_1121956] as he/she reads the chart by [CONTACT_811097] (or study form).  Letters read incorrectly, or 
for which no guesses are made, are marked by [CONTACT_1299] a “X” through the letter on this form. 
Each letter read correctly is scored as one point.  The score for each line (including zero if no 
letters were read correctly on that line) and the total score for the eye are recorded on the 
form, as soon as the four meter testing has been completed.   If the number of letters read 
correctly at four meters is less than twenty, the test should be repeated at one meter and both 
the four -meter and one-meter totals should be recorded on the ETDRS score the one- meter 
test distance. It is strongly advised that the total number of letters correctly read at our meters be calculated as soon as the four meter testing has been concluded in order to identify subjects who require one meter testing.   The subject must sit for testing at the one- meter 
distance.  The same procedure for obtaining visual acuity for the right eye is used for the left 
eye, except that ETDRS Visual Acuity Chart 2 is used. Chart 1 should never be exposed to the left eye and chart 2 should never be exposed to the right eye, even when switching charts and occlusion. 
 
Poor Vision Testing:  Follow the procedures described above, Visual Acuity Testing using the 
EVA System.  
 
Calculating the Visual Acuity Score: After e ach measurement of visual acuity the  score for 
the visit is calculated . The visual acuity score is defined as follows:  
If twenty or more letters are read correctly at the four -meter test distance, the visual acuity 
score is equal to the number of letters ( N) read correctly at four meters..  If one or more but 
less than twenty letters are read correctly at four- meter distance, the visual acuity score is 
equal to the number of letters read correctly at one meter in the first six lines.  If no letters 
are read  correctly at either the four- meter distance or the one- meter distance, the visual 
acuity score is 0, and testing for counter fingers or worse should be performed.   
Page [ADDRESS_1121957] from line to line. The size of the letters is 4.9 × 4.9 cm (2 × 2 inches).  
There  are different sets of letters on each chart, depending on the percentage of contrast being 
tested .  The manufacturer recommends a testing distance of 2.52 m from patient when using 
the translucent 1.25% low contrast symbols chart and 2 m from patient when using the 
translucent 2.5% low contrast symbols chart, which corresponds to a spatial frequency of 
about [ADDRESS_1121958] 3 letters are correctly seen is marked as the result.  
Illumination and Mounting of the chart :  The light box will  be hung on the wall or placed 
on a stand at a height such that the top of the 3rd row of letters (0.8 LogMAR) is 49 + 2 inches (124.5 + 5.1 cm) from the floor.  Room lighting should be approximately [ADDRESS_1121959] : Subjects will be tested before dilating their pupi[INVESTIGATOR_811058].  The subject should sit directly in front of the chart so that the distance from the eyes to the chart is 2.52 meters (100 inches).  
 Recording the subject performance : Full study ID of the subject, the date and the 
technician’s name [CONTACT_811120] . A subject will make a single attempt 
to name [CONTACT_811121], starting with the letters on the first line, then reading 
downward line by [CONTACT_4548]. On the scoring sheet , correctly read letter will be circled or underlined 
and incorrect letter will be stroked through.  Patient Effort:  Subject will be made to guess even when they believe that the letters are 
invisible.  (Several seconds should be allowed for the faintest letters to appear, but subject 
should not give up until he or she has guessed incorrectly 2 of the 3 letters in a triplet. 
 
Testing  the other eye:  Each eye will be tested separately ; always testing the right eye first 
while the left eye is occluded, then alternating to test the fellow eye.  The technician will begin  
with the translucent 1.25% low contrast sensitivity chart at 2.52 m , then changing the chart to 
the translucent 2.5% low contrast sensitivity chart.    . 
 Life and care of the chart:  The chart will not be used if it is marred by [CONTACT_811098], e.g. 
fingerprints.   Chart will be wiped using soft cloth with diluted solution of mild soap and rinsed 
with clean water.  
 Explaining the test :  The subjects will learn  about the chart and the procedure. ‘Try reading 
just one letter at a time’ . ‘Try blinking’, or ‘Do you see something against the white 
blackboard?’ 
 
Page 46 of 84   Standardization : These instructions accompanying a chart have been designed to achieve the 
highest possible comparability of results among different users.   The chart follows the 
luminance, font, and letter spacing recommendations of the Committee on Vision of the 
National Academy of Sciences and National Research Council (1980).  
6.2.2 Visual field mean deviation  
In this study, we will evaluate visual field with the Humphrey threshold static perimeter map . 
In static threshold perimeter we map the island of vision using a different technique.   In the 
classic "30 -2" test on the Humphrey Field Analyzer, 76 points are tested over the patient's 
central 30° of vision. The technician then determines a threshold of light sensitivity for each 
of these points. This intensity of the stimulus is seen 50% of the time, and it can be likened to 
the depth or thickness of an island at each of these points. The mean deviation (MD) calculates the mean of the deviation in the patient's results from the age- corrected normal 
database. The calculati on is center -weighted so that central points contribute more to the 
overall score than peripheral points.  In other words, the MD is the average measure of how 
depressed the patient's visual field is compared with a normal person of the same age.  
Instruct ion to the subjects:  The subjects will be explained that the test is a computerized 
machine test.  The subject will be instructed to look straight ahead and informed to look at the 
steady white light inside the machine all the times.  They will be informe d to push the button 
when they see the flash of light and blink after they push the button.  They will be informed 
about the bright and dim light and the need to have them to test for sensitivity of your eyes. The test will take around [ADDRESS_1121960] instructions:  Subjects will be asked to wash their hair and avoid hair 
chemicals.  Also, to take a good night sleep and bring their corrective eye wear with them. 
Test duration:  The average test takes 30-[ADDRESS_1121961] method:  The test will be done by [CONTACT_811099]. Both eyes will be tested individually.   One eye will be covered and with the other eye, which is being tested , subject 
will watch a screen.  
 
6.2.4 Intraocular Pressure  Measurement (IOP)  
In this study the intraocular pressure will be measured by [CONTACT_811100] (Goldmann) Tonometry method. This type of tonometry uses a small probe to gently flatten part of your 
Page [ADDRESS_1121962] Preparation:   The subject will be asked to remove contact [CONTACT_811101]. 
They will be instructed to remove or loosen any tight clothing around their neck, as pressure 
on neck veins can increase the pressure inside eyes and asked to stay relaxed.  
Duration for the test:  The test will take few minutes to complete.  
Test description:   The subjects will be asked to rest their chin on a padded support and stare 
straight into the microscope (slit lamp). A bright light will shine in subject’s eyes and the 
tonometry probe will be gently touched to the examining eye. The subjects will be instructed, 
to not rub eyes 30 minutes until the numbing medicine has worn off. Avoid blinking or 
squeezing eyes.  There is a very slight risk that the cornea may be scratched during the 
methods that involve touching a tonometer to the eye.  
6.2.5 Spectral Domain - Optical Coherence Tomography  
In this study, technicians using the Heidelberg Spectralis will capture one 20°x20° volume scan at high speed with a 5/frame rate and 97 B -scans. Additionally, a 20°x20° high 
resolution cross hair scan is performed at a 10/frame rate.  
OCT Technician Certification : All  technicians performing OCT will be certified for the 
relevant study procedure before submitting actual study subject scans. Only certified OCT technicians are allowed to take baseline (screening visit scans). The baseline measurements for a subject are critical since all follow up measurements are compared to this point to 
determine the study outcome. 
 
Subject Preparation: The subject will be asked to sit comfortably and look straight ahead to 
the beam of light and avoid blinking. The chin and forehead wil l be rested against support.  
 
6.2.6 National Eye Institute Visual Functioning Questionnaire (NEI- VFQ -25) 
The subjects in the study will be answering a questionnaire of 25 questions pertaining to vision as per the National Eye Institute version 2000. 
• The su bjects can take as much as time needed and should try to complete the forms on 
their own. If they need any assistance they could ask for assistance.  
• If the subjects have glasses/ contact [CONTACT_13293], they should answer the questions as though they 
are wearing them.  
• The subjects will be assured about confidentiality and the information will be used only 
for the study purpose.  
• The scoring data will be analyzed by [CONTACT_811102], by [CONTACT_811103], and by [CONTACT_811104].  
 
6.2.[ADDRESS_1121963]  (SDMT) detects cognitive impairment in less than [ADDRESS_1121964] for busy clinicians to screen for organic 
Page 48 of 84   cerebral dysfunction i n both children (8 years and older) and adults. In this study, this test 
will be performed with standardized method. 
Instructions for administration:  The test can be taken by [CONTACT_811105]. If it is 
given to groups, the papers should be given out f ace down, so that everyone turns over at the 
same time when instructions are given. The following  are the principal instructions that all 
subjects will receive.  
• Look at the Key at the top of the page. Each of the shapes goes with its own number, 
shown in t he box beneath. 
• Practic e giving each shapes the right number in the second line – stoppi[INVESTIGATOR_811059]. 
• After the practice is completed and checked, do them one at a time, starting at the vertical 
double line. • When you finish a line, go to the next. Don’t stop to correct a mistake – just write over it. 
Do as many as you can in a minute and a half. Work quickly. 
• Be prepared to stop immediately when you are told.  
• After [ADDRESS_1121965] LogMar VA  from baseline (week 1) to 
initial post treatment (week 8). Each outcome will be modeled separately  within each cohort . We 
will use mixed effects linear regression to model all available VA measures from week 1 to week 
8.  Fixed effects will be randomization assignment (treatment vs. SHAM), time, and randomization assignment x time interaction.  We will treat time as a categorical variable to allow 
for the most flexibility in mod eling the shape of the VA trajectories over time. Correlation among 
repeated measurements will be modeled using an appropriate within subject covariance structure.  
Unstructured, compound- symmetric, heterogeneous compound symmetric and first -order 
autoregr essive structures will be considered with the final choice being determined using the 
Akaike information criterion (AIC)  and Bayesian information criterion (BIC) statistics. 
Satterthwaite’s approximation will be used to estimate denominator degrees of freedom. We will examine the distribution of the residuals to assess the reasonableness of the normality assumption, 
and will apply appropriate transformations as needed.   
It is important to note that the three cohorts (ophthalmic trauma , MS or CIS, and NAION) cannot 
be pooled as they are clinically distinct populations and the natural history is different in the 
groups. Ophthalmic  trauma results in both anterograde and retrograde degeneration of the afferent 
visual system. This degeneration continues after th e initial insult and further degeneration may be 
Page 49 of 84   preventable or even reverse early damage with intervention(s)  instituted between [ADDRESS_1121966] with alpha=0.05.     
7.[ADDRESS_1121967] sensitivity, VEP results 
(peak latency, amplitude of the p100 wave),  IOP, SD -OCT  nerve thickness, NEI -VFQ -[ADDRESS_1121968] Estimate of Efficacy  
Since the initial SHAM -Randomized group will also receive the active treatment, we will 
calculate an additional estimate of treatment efficacy for each outcome using only data 
from this arm. A similar mixed effects regression analysis will be performed using study period (SHAM vs. active TES) rather than randomization assignment. Study t ime will be 
entered as pre-sham, post-sham, and post- active TES.  The secondary estimates of treatment 
efficacy will be calculated as change from post-sham to post- active TES minus change 
from pre -sham to post-sham.   
7.2.2Long -term Changes  
Using data from all subjects, we will estimate the long -term effects of treatment. We will 
include all available data from the initial Treatment -Randomized group and all data from 
visits 8 -17 from the initial SHAM -Randomized group. We will again use mixed effects 
linear r egression to model the change in outcomes over time. Fixed effects will include 
time (relative to pre -treatment time) and randomization assignment (to control for possible 
period effects). We will use linear contrasts to estimate the change from post- treatment to 
week [ADDRESS_1121969] based our sample sizes on efficacy data reported in a similar study of patients with RP (22).  In that study, average improvement in LogMAR VA for the SHAM group was 0.017 
(SD=0.05) and for the active treatment (150% of threshold) group was .067 (SD=0.05) for a difference in change scores of 0.[ADDRESS_1121970] 80% power to detect a true effect size of [ADDRESS_1121971] with a Type -I error rate of 5% requires 39 subjects (26 
initial treatment; 13 SHAM). Allowing for roughly 5% attrition during the initial treatment 
period, we will aim to randomize [ADDRESS_1121972] size with a 95% CI of wid th +/- 0.69.  That is, if the  
observed effect size were 0.8, the 95% CI would extend from 0.[ADDRESS_1121973] 
size were 0.4, the 95% CI  would extend from -0.[ADDRESS_1121974] deviation of 0.05, if t he observed average difference in change scores is 
0.07, the 95% CI would extend from 0.036 to 0.10.   
7.4 Datasets  
7.4.1 Full Data Set  
This data set is the “intent -to-treat” data set and includes all randomized subjects with 
baseline and/or follow -up data for the primary and secondary outcomes. Subjects are 
analyzed as they are randomized, regardless of the amount of treatment received. This 
data set will be analyzed for primary and secondary efficacy outcomes.   
7.4.2 Per-protocol Data Set 
This data set includes all randomized subjects with baseline and/or follow -up data for the 
primary and secondary outcomes who received at least [ADDRESS_1121975] treatment (SHAM 
instead of initial treatment or vice versa) will be excluded. Any subject found to be ineligible after randomization will also be removed from this data set. A nalyses specified 
under section 7.[ADDRESS_1121976] -
treatment.   
7.5 Primary Hypothesis 
As in the case of central nervous system strokes, in whic h there is a central area of irreversible 
infar ction and a border zone of tissue that has some normal anatomic structure but does not 
function (so called "ischemic penumbra,” akin to a state of hibernation), we postulate that some cells and axons of the optic nerve and retina are damaged by [CONTACT_811081]. We hypothesize that because vision is a physiological function uniting a 
biochemical pathway with an electrical signal that providing a  controlled, well-defined, safe 
electrical stimulus has the potential to restore function to photoreceptors, glial cells , and axons 
that are not irreversibly damaged.    
7.[ADDRESS_1121977] binomial confidence interv als. Rates between arms during the initial treatment period 
will be compared using Fisher’s exact test. Safety evaluation issues are described in detail in 
Attachment 2, Human Subjects Recruitment and Safety Procedures.   
8. RESTRICTIONS  
8.1 Prohibited Med ications  
History of epi[INVESTIGATOR_811047]/or prescribed to anti- epi[INVESTIGATOR_811048] -seizure medication.  
 
8.[ADDRESS_1121978] at study entry/screening  and at each treatment visit prior to treatment. 
Subjects cannot have history of e pi[INVESTIGATOR_811047]/or prescribed to anti -epi[INVESTIGATOR_110330]/or anti-
seizure medication.  
9. EVALUATION OF ADVERSE EVENTS  
9.1 Definitions 
An adverse event (AE) is defined as any new medical problem, or exacerbation of an existing  
problem, experienced by a subject while enrolled in the study, whether or not it is considered device- related by [CONTACT_093].  
9.2 Relationship to the Investigational Device 
The investigator should assess the relationship of the adverse event to the investigational device.  The relationship should be assessed using the categories in Table 8.2 -1 below.   
Table 9.2 Possible Relationship Between Adverse Events and Investigational Device  
Probably Related  It is more likely than not that there is a reasonable causal 
relationship betwe en treatment with the investigational device and 
adverse event.  
Possibly Related  There is a reasonable relationship to the device treatment, but the causal relationship is unclear or lacking.  
Not Likely Related  There is a temporal relationship to the device treatment, but there is not a reasonable causal relationship between the study device and 
Page 52 of 84   the event.  For example, the adverse event occurs in a time relation 
to the device treatment, which makes relation improbable.  
Unrelated  No relationship between treatment with the investigational device 
and the adverse event exists.  
 
9.3 Unanticipated Adverse Device Effects (Events) 
An unanticipated adverse device effect is defined as "any serious adverse effect on health or 
safety, or any life-threatening problem, or death caused by, or associated with, a device; if that 
effect, problem, or death was not previously identified in nature, severity, or degree of incidence 
in the investigational plan, or application (including supplementary application), or any other unanticipated serious problem associated with a device that relates to the rights, safety, or welfare 
of subjects."  
If an unanticipated adverse device effect occurs, the investigator should promptly notify the 
sponsor of such an event, within [ADDRESS_1121979] learning  of the event.  
9.4 Serious Adverse Events 
Each adverse event should be assessed for its seriousness.  The definition below should be used 
for this assessment.  Please note that the term serious adverse event is not synonymous with a "severe" adverse event,  which may be used to describe the intensity of an event experienced by 
[CONTACT_423].  (Please refer to Section 9.6 for severity definitions.)  
An adverse event should be classified as serious if it meets any of the following criteria:  
• Results in, or contributes to, a death;  
• Is life -threatening (i.e., the subject was, in the opi[INVESTIGATOR_871], at risk of death at 
the time of the event, but it does not include an event that, had it occurred in a more severe form, might have caused death); 
• Results in permanent disability or incapacity (i.e., permanent impairment of a body function 
or permanent damage to a body structure); 
• Requires in -patient hospi[INVESTIGATOR_34908];  
• Necessitates medical or surgical intervention to prevent death or a life-threatening condition, 
or to preclude a permanent disability or incapacity; and,  
• Results in a congenital anomaly or birth defect.   
 
Non-serious adverse events are all events that do not meet the criteria for a "serious" adverse 
event.  
9.[ADDRESS_1121980]'s case report form. The Wills Eye IRB  will conduct an 
Page [ADDRESS_1121981] report serious adverse events to his/her I RB according to 
the IRB requirements at the study site.  
 9.[ADDRESS_1121982], using the following. 
1 = Mild - Discomfort noticed, but no disruption to daily activity  
2 = Moderate - Discomfort sufficient to reduce or affect normal daily activity  
3 = Severe - Inability to work or perform normal daily activity  
 
 9.[ADDRESS_1121983]'s death, regardless of whether the death is related 
or unrelated to the investigational device.  The investigator should attempt to determine, as 
conclusively as possible, whether the death is related to the device.  The cause of death and the investigator's discussion regarding whether or not the death was device-related should be described in a written report. The investigator must report death to their IRB according to the IRB 
regulations a t the study site.  
 9.[ADDRESS_1121984] result, the investigator needs to ascertain if this is an abnormal (i.e., clinically significant) change from  baseline for that individual subject.  (This determination, however, does 
not necessarily need to be made the first time an abnormal value is observed.  The investigator may repeat the laboratory test or request additional tests to verify the results of the original 
laboratory tests.)  If this laboratory value is determined to be an abnormal change from baseline 
for that subject, this should be considered an adverse  
 9.10 Independent Study Oversight (Data Safety Monitoring Board) 
WEHS  will establish a Data Safety and Monitoring Board (DSMB) for this research project. 
These groups will assure protocols are being followed properly, case reports match the source documents, inclusion/exclusion criteria are being followed, and all subjects are consented properly. In addition, the DSMB will review safety data and visit after we have enrolled ten 
subjects after which we will initiate site visits every six months . The DSMB will meet with the 
research team on a quarterly basis.  
 9.10.[ADDRESS_1121985] Ch airperson Roles and Responsibilities  
Page 54 of 84   By[CONTACT_180092], MD is appointed t he DSMB Chairperson  and will also serve as the Research 
Monitor for this study.  By[CONTACT_811106]: 
• Reviewing and evaluating accumulated study population data, analyzing patie nt 
safety, and study conduct and progress 
• Overseeing the assurance that the study protocols are being followed properly  
• Ensuring all participants meeting the eligibility criteria are consented properly and 
thoroughly 
• Organizing and developi[INVESTIGATOR_007] a monitoring plan in collaboration with the members of the DSMB, which will begin  after ten subjects have been  enrolled  into the study  by 
[CONTACT_811107] 
• Track and report to the IRB factors that might affect overall study outcomes and 
compromise confidentiality of study data, such as violations of protocol, randomization, or masking procedures 
• Observing consistency and accuracy of case report forms and source documents  
• Monitoring the transfer and analysis of de- identified participant results and other case 
sensitive study material between the research team members involved in the study   
• The chairperson “has the authority to stop the research protocol in progress, remove individual human subjects from a research protocol, and take whatever steps are necessary to protect the safety and well being of human subjects until the IRB assesses the independent Research Monitor's report."  
• The chairperson is "required to review all unanticipated problems involving risk to 
subjects or others, serious adverse events and all subject deaths associated with the 
protocol and provide an unbiased written report of the event. At a minimum, the 
research monitor must comment on the outcomes of the event or problem and in case of a se rious adverse event or death, comment on the relationship to participation in 
the study. The research monitor must also indicate whether he/she concurs with the details of the report provided by [CONTACT_458]. Reports for events 
determined by [CONTACT_811108]."  
9.10.2 DSMB Reporting Requirements to the local IRB 
The DSMB wil l develop a monitoring plan and provide procedures for transmitting the 
DSMB’s summary reports to the IRB.  The DSMB will issue a written summary report to 
the IRB and the study’s Principal Investigator.  The report will provide individual findings, overal l safety assessment and recommendations.  The summary report will 
reflect familiarity with the study’s protocol, proposing appropriate analyses of participant enrollment, site visits, study procedures, study documents completion, data quality, and losses t o follow-up.  The report should also inform study investigators of the DSMB 
members’ conclusions with respect to the study’s progress or need for modification of the 
protocol.   
 
10 RISK ANALYSIS    
 10.1 Potential Risks  
Page 55 of 84   10.1.1 Corneal Abrasion  
The OkuStim® device may result in mechanical irritation of a subject’s cornea, 
which may be observed together with red eye and/or dry eye sensation. In this case, conventional eye drops (contact [CONTACT_811109]) or artificial tears can alleviate the irritating sensation. In case the irritation does not disappear within 1-[ADDRESS_1121986] any progression of discoloration. 
Immediately after receiving TES, subjects’ eyes will be flushed with a buffered saline 
solution to reduce the presence of silver particles. In addition, an external photo will be 
taken of the subjects’ conjunctiva and cornea. If any discoloration appears, the subject 
will be notified immediately.  
   
 10.[ADDRESS_1121987] a successful human study to model 
our protocol and gain OkuStim®-specific knowledge from. In addition, the WEHS will 
take all necessary precautions to minimize the risk of an adverse event to the best degree possible. Only personnel who are trained on how to properly use the device by [CONTACT_811110]® technicians will be able to administer it, regardless of whether treatment administered is 
SHAM or authentic. Since all TES administration will take place on site at the WEHS, 
subjects will have access to immediate ophthalmic care if an adverse event or emergen cy 
arises. In addition, all members of the research team will be educated on the device, including its risks, hazards and commonly encountered problems, in order to prepare for an emergency scenario. During the treatment period, and for nine months afterwa rds, subjects 
will be able to contact [CONTACT_811111] a result of TES intervention.  Though an emergency is highly unlikely, the 
WEHS will instruct all study personnel on how to operate and handle emergency scenarios should they arise. Furthermore, in the event of physical injury or illness resulting to the subject as a direct result of the treatments used in this investigation, comprehensive medical 
and/or surgical care (including hospi[INVESTIGATOR_12191]) to the extent needed and available will be 
Page 56 of 84   provided.  However, Wills Eye Health System cannot assure that this comprehensive 
medical and/or surgical care will be provided without charge, and the costs incurred for this care may ultimately be the subj ect’s responsibility. In this regard, our study thoroughly 
minimizes risks to subjects to the best of our capability.  
 10.[ADDRESS_1121988] potential benefit available to subjects participating in the study is the rehabilitation and restoration of vision after having endured debilitating ocular trauma. If the proposed TES treatment can be shown to significantly improve VA in our subjects (improvement by 2 lines or 
more upon re- evaluation) then we may be able to adapt these findings to improve overall visual 
function in our wounded military personnel, and in doing so alleviate some of the anxiety of their straining careers.  
 10.4 Justification for the Clinical Study 
Reports show potential efficacy using transcorneal electrical stimulation (TES) to improve visual 
function (16- 22). Therefore, the success of electrical stimulation in these neuro- degenerative 
disorders provides a reasonable rationale and significant precedent to investigate its potential in 
disorders of the optic nerve and retina, which function via an integration of biochemical and electrical interactions.  
11. DEVICE MANAGEMENT  
11.[ADDRESS_1121989] their 
origin in the Declaration of Helsinki, and in accordance with applicable local and federal 
regulatory requirements and the laws in the country in which the study is being conducted, and in 
accordance with the standards of good clinical practice.  In the United State s, the study will 
conducted in accordance with the  Protection of Human Subjects Regulations, including Subpart 
B Informed Consent of Human Subjects (21 CFR Part 50) ; the Institutional Review Board 
Regulations (21 CFR Part 56); the Financial Disclosure by [CONTACT_453416] (21 
CFR Part 54); and the Investigational Device Exemptions Regulations (21 CFR Part 812).   
12.[ADDRESS_1121990]/Ethics Committee 
Prior to initiation of any study procedures, the protocol, informed consent and device labeling 
will be submitted to a duly constituted IRB for review and approval.  In addition, any 
Page 57 of 84   amendments to the protocol or informed consent form will be reviewed and approved (if 
necessary) by [CONTACT_1201].  The sponsor must receive a letter documenting the IRB approval at the clinical site prior to the initiation of the study.    The investigator is responsible for providing the appropriate reports to its reviewing IRB during 
the course of the clinical study.  The investigator shoul d refer to his/her site- specific 
requirements.  In the [LOCATION_002], this will include the following at a minimum:  
• Informing the IRB of the study progress periodically as required, but at least annually;  
• Reporting any unanticipated adverse device effects within [ADDRESS_1121991] 
learning of the event;  
• Reporting any deviations from the clinical protocol to protect the life or well- being of a 
subject in the case of an emergency within 5 working days after the emergency occurred;  
• Reporting the use of the device without obtaining informed consent from a subject within 5 working days of the event; and,  
• Providing any other reports requested by [CONTACT_1201].  
• Notifying the IRB of study completion within [ADDRESS_1121992] not be 
disclosed to any persons not directly concerned with th e study without written prior permission 
from the sponsor.  Authorized regulatory officials and sponsor personnel (or its representatives) 
will be allowed full access to inspect and copy the records.  All investigational devices and/or other materials collected should be used solely in accordance with this protocol, unless otherwise agreed to in writing by [CONTACT_456]. 
Subjects should be identified only by [CONTACT_811112].  If 
necessary, their full names may be made known to a regulatory agency or other authorized 
officials.  
13. REPORTS AND RECORDS MANAGEMENT  
This investigational study will follow the investigator report and record keepi[INVESTIGATOR_811060] [ADDRESS_1121993] provide the following documentation to the sponsor:  
• Investigator Agreement, signed by [CONTACT_093], which lists any physicians who  will 
be involved in conducting the investigation under the direction of the primary investigator.  
• A copy of the investigator's curriculum vitae (CV) as well as copi[INVESTIGATOR_407451] -
investigators.  
• A letter signed by [CONTACT_811113].  
• A copy of the IRB approved informed consent document. 
Page 58 of 84   During the study, investigators are required to maintain on file the following accurate, complete 
and current records relating to this study as described in 21 CFR § 812.140.  A summary of these 
records is described below:  
• All correspondence and required reports which pertain to the study; 
• Records of receipt, use or disposition of the investigational device, including the type and 
quantity of the device, the dates of receipt, the lot number, the names of all persons who received, used or disposed of each device, and why and how many units of the device have been returned to the sponsor, repaired, or otherwise disposed; 
• Records of each subject's case history and exposure to the device;  
• Signed and dated consent forms; 
• Relevant observations, including records concerning adverse events, condition of each subject upon entering and results of diagnostic tests;  
• Case report forms and corrections to the forms;  
• Protocol, amendments and case report forms; 
• Subject recruiting materials; and,  investigator curricula vitae.  
13.2 Investigator Reports 
Investigators are required to prepare and submit to the sponsor the following complete, accurate, 
and timely reports on this investigation when necessary.  These reports, which follow, include all 
of those described 21 CFR § 812.150, and some additional reports requested by [CONTACT_456]: 
• The in vestigator will notify the sponsor of a subject death occurring during the 
investigation, as soon as possible preferably within [ADDRESS_1121994]'s 
death, but in no event later than [ADDRESS_1121995] death as specified by [CONTACT_1201].  
• The investigator will notify the sponsor of any unanticipated adverse device effects 
within [ADDRESS_1121996].  
• The investigator will notify the sponsor of the withdrawal of IRB approval, as soon as possible, but no later than [ADDRESS_1121997] learns of the 
withdrawal.  
• The investigator will provide current progress reports to the sponsor and reviewing IRB at regular intervals and at least on an annual basis.  
• The investigator will notify the sponsor and revie wing IRB of any deviation from the 
investigational plan to protect the life and physical well-being of a subject in an 
emergency, as soon as possible, but no later than 5 working days after the emergency occurred. 
• The investigator will notify the sponsor a nd reviewing IRB that an informed consent was 
not obtained from a subject, as soon as possible, but no later than 5 working days after 
such an occurrence. 
• The investigator will provide a final summary report within 3 months after termination or 
completion of the study to the sponsor and reviewing IRB. 
• The investigator will provide any other information upon the request of an IRB, 
regulatory authorities, or the sponsor. 
Page [ADDRESS_1121998]'s visit to the clinic, an investigator participa ting in the study will record 
progress notes to document all significant observations.  In addition, any contact [CONTACT_811114].  
For transmission to the sponsor, information from the study progress notes and other source 
documents will be promptly transcribed in black ink to case report forms.  Attachment [ADDRESS_1121999] 2 years after the latter of the following two dates:  
• The date on which t he investigation is terminated or completed; or,  
• The date the records are no longer required for purposes of supporting a premarket approval application.  
The investigator must not dispose of any records relevant to this study without either (1) written permission from the sponsor or (2) providing an opportunity for the sponsor to collect such records.  The investigator shall take responsibility for maintaining adequate and accurate 
electronic or hard copy source documents of all observations and data genera ted during this 
study.  Such documentation is subject to inspection by [CONTACT_811115]. 
 
14. MONITORING PROCEDURES  
14.1 Monitoring 
Wills Eye has ethical, legal and scientific obligations to carefully follow this study in a detailed 
and orderly manner in accordance with established research principles and FDA regulations.  As part of a concerted effort to fulfill these obligations (maintain current personal knowledge of the 
Page 60 of 84   progr ess of the study), Wills Eye will hire a data safety monitoring board to visit the site during 
the study in addition to maintaining frequent telephone and written communication.   
The following guidelines are provided to describe the Wills Eye's procedures for monitoring the 
clinical studies.  If the investigator is not comply ing with the signed Investigator Agreement, the 
protocol, or any condition of the study (e.g., incomplete data forms), the sponsor has the right to 
terminate the investigator's participation in the study.  Wills Eye will seek highly respected and 
qualified ophthalmologists and scientists with  training and experience to conduct monitoring of 
the trial, and for ensuring the quality of the study monitoring visits by [CONTACT_2037]. 
14.2 Pre-Study Monitoring Procedures  
14.2.1 Selection of Monitors 
There will be an  overall study monitor, as well as two other monitors, for the 
investigational stud y.  Wills Eye will  determine the total number of monitors for its 
investigational studies based on the size and complexity of the study, the number and location of sites, the number of subjects, and the scope of the contractual obligations at 
each site.  All monitors are to be qualified by [CONTACT_8640], training, and experience.   
14.2.2Clinical Investigators 
Upon receipt of a signed Investigator Agreement, and IRB approval lett er, investigators 
will be sent the appropriate clinical study materials.  
14.3 Pre-Investigation Visit 
A monitor will be responsible for determining and documenting that each investigator clearly understands and accepts the responsibilities and obligations incurred in conducting a clinical 
study.  The monitor will ensure prior to study initiation that the investigator:  
• Understands the requirements for a well-controlled study; 
• Understands the nature of the clinical protocol;  
• Understands his/her reporting obli gations;  
• Understands the requirements for device accountability;  
• Understands and accepts the obligations to obtain informed consent in accordance with 21 CFR Parts 50 and 56; 
• Understands and accepts the obligation to obtain IRB review and approval of the c linical 
investigation before it is initiated and to ensure continuing review of the study by [CONTACT_224534] 21 CFR Part 56, and to keep the sponsor informed of all IRB actions concerning the study; 
• Understands and accepts the requirements regar ding financial disclosure of clinical 
investigations, 21 CFR Part 54; 
• Has adequate facilities and access to an adequate number of suitable subjects to conduct 
the investigation; and,  
• Has the required documentation on file, including IRB approval and a signed investigator 
agreement.  
 
Page 61 of 84   14.4 Periodic Monitoring Visits 
Monitoring visits will be conducted in accordance with the FDA Guideline for the Monitoring of 
Clinical Investigations, January 1988.  The monitor should visit each site frequently to ensure the following: 
• Facilities continue to be adequate and acceptable.  
• The protocol is being properly followed. 
• The IRB has approved or been notified of any protocol changes. 
• Accurate, complete and current records are being maintained, and the information recorded and submitted to the sponsor is representative of the subject's record and other supporting documentation. 
• Accurate, complete and timely adverse event reports are being submitted to the sponsor.  
• Informed consent has been obtained. 
• The reason for a subject's withdrawal from the study has been documented. 
• Reports are being submitted to the IRB and sponsor.  
• The appropriate staff is carrying out study activities.  
The investigator or designee must, upon request, provide to the sponsor or FDA investigator the necessary study records for a thorough review of the study's progress.  These records include, but 
are not limited to, case report forms and original documents and records such as hospi[INVESTIGATOR_811061], consent forms, and operative reports.  
All case rep ort forms and other documentation related to the study will be reviewed upon receipt, 
and the site will be promptly notified of any deficiencies.  
14.5 Frequency of Monitoring Visits 
The frequency of monitoring visits will be determined on the basis of seve ral factors, including:  
• Duration of the study; 
• Number of outstanding issues from previous visits; 
• Number of subjects enrolled; 
• Number of investigators/sites; and,  
• Complexity of the study. 
Each site will undergo a monitoring visit at least monthly.  
14.[ADDRESS_1122000] be performed prior to the study termination visit; the study 
termination visit may be combined with a monitoring visit.  The following tasks should be completed at the last visit by [CONTACT_2037].  
• Ensure that all forms have been sent to the sponsor. 
• Remind the investigator of the obligation to retain the records. 
• Prepare final monitoring report for sponsor and IRB. 
14.[ADDRESS_1122001] include the following 
information:  
• Date of the visit;  
• List of study site personnel present; and,  
• A summary of the findings, problems, and actions taken to correct any deficiencies. 
Page [ADDRESS_1122002] not be 
disclosed to any persons not directly concerned with the study without written prior permission from 
the sponsor.  Authorized regulatory officials and sponsor personnel (or their representatives) will be allowed full access to inspect and copy the records.  All investigational devices, subject bodily fluids, 
and/or other materials collected should be used solely in accordance with this protocol, unless 
otherwise agreed to in writi ng by [CONTACT_456]. 
 
Subject names and identifiers will be coded for privacy and subjects will be identified only by [CONTACT_811116].  If necessary, their full names may be made known to a 
regulatory agency or other authorized of ficials.  
16. AMENDMENT POLICY 
The investigator will not make any changes to this protocol without prior written consent from the 
sponsor and subsequent approval by [CONTACT_1201], except if the deviation from the protocol is necessary to 
protect the life and phys ical well -being of a subject in an emergency.  Such protocol deviations must 
be reported to the sponsor and the reviewing IRB as soon as possible, but no later than 5 working days after the emergency occurred.  
Any permanent change to the protocol, whether it is an overall change or a change for specific study 
center(s), must be handled as a protocol amendment.  Any amendment to the protocol that appears 
indicated as the study progresses will be fully discussed by [CONTACT_093](s) and the sponsor.  If agreement is reached regarding the need for an amendment, the sponsor will write it.  The written amendment must be submitted to the chairman of the IRB identified with this responsibility.  Except 
for "administrative amendments", investigators must await IR B approval of protocol amendments 
before implementing the change(s).  Administrative amendments are defined to have no effect on the 
validity of the data or information resulting from the completion of the approved protocol, or the relationship of likely p atient risk to benefit relied upon to approve the protocol; the scientific 
soundness of the investigational plan or protocol; and, the right, safety or welfare of the human 
subjects involved in the investigation.  
When, in the judgment of the chairman of the local IRB, the investigators and/or the sponsor, the amendment to the protocol substantially alters the study design and/or increases the potential risk to 
the subject, the currently approved written informed consent form will require similar modificatio n.  
In such cases, repeat informed consent will be obtained from subjects enrolled in the study before 
continued participation. 
 
Page [ADDRESS_1122003], Philadelphia PA 
[ZIP_CODE].  Julia Haller, MD is the Principal Investigator.  
Page 64 of 84    
REFERENCES  
 
1. Hornblass A. Eye Injuries in the military. Int Ophthalmol Clin. 1981;21:121-138. 
2. Iskow C. From war injured to the elderly: brain injuries are on the rise for vision rehabilitation 
practit ioners. J Vis Impair Blind.  2010;104:597-602. 
3. Weichel ED, Colyer MH, Ludlow SE, Bower KS, Eiseman AS. Combat ocular trauma visual outcomes during operations Iraqi and Enduring Freedom. Ophthalmol. 2008;115:2235-2245. 
4. Goodrich GL, Kirby J, Cockerham G, et al. Visual function in subjects of a polytrauma rehabilitation center: a descriptive study. J Rehabil Res Dev.  2007;44:929–936. 
5. Brahm KD, Wilgenburg HM, Kirby J, et al. Visual impairment and dysfunction in combat-injured military personnel: a population study. Optometry and Vision Science. 2009;86:[ADDRESS_1122004] TP, Haller JA. Delayed intraocular foreign body removal without endophthalmitis during operations Iraqi freedom and enduring freedom. Ophthalmol. 2007;114:1439-47. 
7. Radomski MV, Davidson L, Voydetich, Erickson MW. Occupational therapy for service members with mild traumatic brain injury. Am J Occup Ther. 2009;4:646-655. 
8. Lawrence M. Military and VA Perspective. Vision/TBI losses potentially treated by [CONTACT_811117]. NEI/FDA use of functional endpoints in visual prostheses product development. Presentation at the National Eye Institute, NIH, Bethesda, MD. May 6, 2011. 
9. Jensen JE, Conn RR, Hazelrigg G, Hewett JE. The use of transcutaneous neural stimulation and 
isokinetic testing in arthroscopic knee surgery. Am J Sports Med . 1985;13:27-33. 
10. "FAQs." TENS FDA - Drug Free Pain Relief . Web. 27 July 2011. 
http://www.tensfda.org/faqs#!_faqs/what- is-tens. 
11. Nnoaham KE, Kumbang J. Transcutaneous electrical nerve stimulation (TENS) for chronic pain. 
Cochrane Database Syst Rev . 2008;3.  
12. Tan AG, Rintala DH, Thornby [CONTACT_163692], Yang J, Wade W, Vasilev C. Using cranial electrotherapy stimulation to treat pain associated with spi[INVESTIGATOR_1828]. J Rehabil Res Dev . 2006;43:461-474. 
13. Ni Z, Pi[INVESTIGATOR_7125], Lang AE, Chen R. Involvement of the cerebellothalamocortical pathway in Parkinson disease. Ann Neurol. 2010;68:816-824. 
14. Hopyan T, Gordon KA, Papsin BC. Identifying emotions in music through electrical hearing in 
deaf children using choc hlear implants. Cochlear Implants Int. 2011;12:21-26. 
15. Wellens HJ, Schulenburg RM, Durrer D. Electrical stimulation of the heart in subjects with 
ventricular tachycardia. Circulation. 1972;46:216-226. 
16. Fujikado T, Morimoto T, Matsushita K, Shimojo H, Okawa Y , Tano Y. Effect of transcorneal 
electrical stimulation in subjects with nonarteritic ischemic optic neuropathy or traumatic optic neuropathy. Jpn J Ophthalmol . 2006;50:266-273. 
17. Inomata K, Shinoda K, Ohde H, Tsunoda K, Hanazono G, Kimura I, Yuzawa M, Tsubota K, Miyake Y. Transcorneal electrical stimulation of retina to treat longstanding retinal artery occlusion. Grafes Arch Clin Exp Ophthalmol. 2007;245:1773-1780. 
18. Morimoto T, Miyoshi T, Sawai H, Fujikado T. Optimal parameters of transcorneal electrical stimulation (TES) to be neuroprotective of axotomized RGCs I adult rats. Exp Eye Res.  
2010;90:285-291. 
Page [ADDRESS_1122005] Ophthalmol Vis Sci. 2005;46:2147-2155. 
20. Ciavatta VT, Kim M, Wong P, Nickerson JM, Shuler RK Jr., McLean GY, Pardue MT. Retinal expression of Fgf2 in RCS rats with subretinal microphotodiode array. Invest Ophthalmol Vi s Sci.  
2009;50:4523-4530. 
21. Ni YQ, Gan DK, Xu HD, Xu GZ, Da CD. Neuroprotective effect of transcorneal electrical stimulation on light-induced photoreceptor degeneration. Exp Neurol.  2009;219:439-452. 
22. Schatz A, Röck T, Naycheva L, Willmann G, Wilhelm B, Pete rs T, Bartz -Schmidt KU, Zrenner 
E, Messias A, Gekeler F. Transcorneal electrical stimulation for subjects with retinal pi[INVESTIGATOR_1802]: 
a prospective, randomized, sham- controlled exploratory study. Invest Ophthalmol.  2011;52:4485-
4496. 
23. Pardue MT, Phillips MJ, Yin H, Sippy BD, Web-Wood S, Chow AY, ball SL. Neuroprotective 
effect of subretinal implants in the RCS rat. Invest Ophthalmol Vis Scie.  2005;46(2):674-682. 
24. Luneau K, Newman NJ, Biousse V. Ischemic optic neuropathies. Neurologist.  2008;14:341-54. 
25. Hayreh SS.  Ischemic optic neuropathy. Prog Retin Eye Res . 2009;28:34-62. 
26. Hattenhauer MG, Leavitt JA, Hodge DO, Grill R, Gray DT. Incidence of non- arteritic anterior 
ischemic optic neuropathy. Am J Ophthalmol. 1997;123:103-107. 
27. Heier JS, Enzenauer RW, Wintermeyer SF, Delaney M, LaPi[INVESTIGATOR_811062]. Ocular injuries and diseases at a combat support hospi[INVESTIGATOR_811063]. Arch 
Ophthalmol.1993;111:795-798. 
28. Weichel ED, Colyer MH, Bautista, BS, Bower KS, French LM. Traumatic brain injury associated with combat ocular trauma. J Head Trauma Rehabil. 2009;24:41-50. 
29. Oono S, Kurimoto T, Kashimoto R, Tagami Y, Okamoto N, Mimura O. Transcorneal electrical stimulation improves visual function in eyes with branch retinal artery occlusion. Clin Ophthal mol. 2011;5:397-402. 
30. Kurimoto T, Oono S, Oku H, Tagami Y, Kashimoto R, Takata M, Okamoto N, Ikeda T, Mimura O. Transcorneal electrical stimulation increases chorioretinal blood flow in normal human 
subjects. Clin Ophthalmol. 2010;4:1441-1446. 
31. Morimoto T, F ujikado T, Choi JS, Kanda H, Miyoshi T, Fukuda Y, Tano Y. Transcorneal 
electrical stimulation promotes the survival of photoreceptors and preserves retinal function in 
royal college of surgeons rats. Invest Ophthalmol Vis Sci.  2007;48:4725-32. 
32. Mangione CM,  Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RD. Development of the 25- item 
National Eye Institute visual function questionnaire. Arch Ophthalmol . 2001;119:1050-1058. 
33. Drake AS, Weinstock -Guttman B, Morrow SA, Hojnacki D, Munschaquer FE, Benedict RH. 
Psychometrics and normative data for the Multiple Sclerosis Functional Composite: replacing the 
PASAT with the Symbol Digit Modalities Test. Mult Scler. 2010;16:228-37. 
34. Benedict RH. Effects of using same - versus alternate-form memory tests during short- interval 
repeated assessments in multiple sclerosis. J Int Neuropsychol Soc.  2005;11:727-36. 
35. Benedict RH, Bruce JM, Dwyer MG, Abdelrahman N, Hussein S, Weinstock -Guttman B, Garg 
N, Munschauer F, Zivadinov R. Neocortical atrophy, third ventricular width, and cog nitive 
dysfunction in multiple sclerosis . Arch Neurol . 2006;63:1301-1306. 
36. Cookfair D, Benedict RH, Gavett R, Gunther M, Munschauer F, Garg N, Weinstock -Guttman B. 
Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS) . J Int 
Neuropsychol Soc. 2006;12:549-58. 
Page [ADDRESS_1122006] RH, Weinstock -Guttman B, Fishman I, Sharma J, Tjoa CW, Bakshi R. Prediction of 
neuropsychological impairment in multiple sclerosis: comparison of conventional magnetic 
resonance imaging measures of atrophy and lesion burden. Arch Neurol.  2004;61:226-30. 
38. Christodoulou C, Krupp LB, Liang Z, Huang W, Melville P, Rogue C, Scherl WF, Morgan T, MacAllister Ws, Li L, Tudorica LA, Li X, [COMPANY_002] P, Peyster R. Cognitive performance and MR 
markers of cerebral injury in cogni tively impaired MS Subjects.  Neurology. 2003;60:1793-8. 
39. Parmenter BA, Weinstock -Guttman B, Garg N, Munschauer F, Benedict RH. Screening for 
cognitive impairment in multiple sclerosis using the Symbol digit Modalities Test. Mult Scler.  
2007;13:52-7. 
40. Wahliq E, Benedict RH, Bakshi R, Fishman I, Munschauer F, Zivadinov R, Weinstock-Guttman B. Predicting quality of life in multiple sclerosis: accounting for physical disability, fatigue, 
cognition, mood disorder, personality, and behavior change . J Neurol Sci . 2005;231:29-34. 
41. Honarmand K, Akbar N, Kou N, Feinstein A. Predicting employment status in multiple sclerosis Subjects: the utility of the MS functional composite . J Neurol. 2011;258:244-9. 
42. Schultheis MT, Weisser V, Ang J, Elovic E, Nead R, Sestito N, Flekshe r C, Millis SR. 
Examining the relationship between cognition and driving performance in multiple sclerosis . 
Arch Phys Med Rehabil . 2010;91:465-73. 
43. Tennstedt SL, Dettling U, McKinlay JB.  Refusal rates in a longitudinal study of older people: implications f or field methods.  J Gerontol . 1992;47:S313-S318. 
44. OkuVision: A Pulse for Vision. Instructions for Use: “OkuStim”, “OkuSpex”, “OkuEl” . Vers. -
Nr. 001 (28. Jan. 2011) . Okuvision GmbH, Gerhard Kindler-Str.8, D-[ZIP_CODE] Reutlingen, 
[LOCATION_013]. www.okuvision.de. Accessed 7/28/2011. 
45. Dougherty AL, Macgregor AJ, Han PP, heltemes KJ, Galarneau MR. Visual dysfunction 
following blast- related traumatic brain injury from the battlefield. Brain Injury.  2011; 25(1): 8-
13. 
46. Cockerham GC, Goodrich GL, Weichel ED, Orcutt JC, Rizzo JF, Bower KS, Schuchard RA. Eye 
and visual function in traumatic brain injury. J Rehabil Res Dev.  2009;46(6):811-818. 
47. Berezovsky A, Martins Pereira J, Rios Salomao S, et al. Validation of a new fiber electrode 
prototype for clinical electroretinography. Arq Bras Oftalmol. 2008; 71(3): 316-[ADDRESS_1122007] for clinical multifocal electroretinography 
2011 edition. Doc Ophthalmol. 2012; 124: 1-[ADDRESS_1122008] changes in patients with abnormalities of the retina. Doc Ophthalmol. 2010 Apr; 120(2): 175-86. 
 